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T lymphocyte-derived malignancies are pediatric cancers often carrying poor prognoses. 
The proto-oncogenes underlying these malignancies frequently are also fundamental to normal 
lymphocyte development and function. Therefore, the discovery of heretofore unrecognized 
lymphocyte oncogenes and tumor suppressors is of potentially profound significance to both 
clinical medicine and scientific understanding.  
To address this, we pioneered a phenotype-driven forward-genetic screen in zebrafish 
(Danio rerio). Using transgenic animals with T lymphocyte-specific enhanced green fluorescent 
protein (EGFP), we performed chemical mutagenesis, screened fish for GFP+ tumors, and 
identified several lines developing heritable T cell malignancies.  One of these lines, oscar the 
grouch (otg), is characterized by recessive inheritance. Validation of otg as a true leukemia 
predisposition model was accomplished using histology, immunohistochemistry, gene expression 
studies, confirmation of clonality, and allogeneic transplantation. 
In search of the genetic mutation underlying otg, we compared in vivo responses to 
glucocorticoids and γ-irradiation (therapies known to affect human T-ALL). Both dexamethasone 
(DXM) and irradiation treatment (XRT) were of limited or no utility in otg. In addition to 
diminished sensitivity, otg larvae were resistant to radiation-induced apoptosis and showed 
decreased activation of caspase 3.  We determined this resistance is due to a block in the intrinsic 
mitochondrial apoptosis pathway.   
To discover genetic changes that may cause T-ALL, and those contributing to relapse, we 
used array comparative genomic hybridization (aCGH) in both humans and zebrafish. We 
identified copy number aberrations (CNAs) in 17 zebrafish T-ALLs, and compared all D. rerio 
genes found in any CNA to a cohort of 75 human T-ALL samples. We found significant overlap 
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(62%) with genes in CNAs from the human T-ALLs. Additionally, 15 genes recurrently altered 
(>3 samples) in zebrafish T-ALL were also in CNAs from 5 or more human T-ALLs. Finally, we 
used aCGH to study CNA genes acquired during iterative allo-transplantations of 3 zebrafish 
malignancies. We compared these genes with human aCGH results from 23 patients who either 
failed induction, or had already relapsed. Again, we observed a large overlap (53%) as well as 9 
genes found in 2 fish and >5 humans. These genes are candidates for causing the increased 
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Background and significance 
T cell acute lymphoblastic leukemia (T-ALL) is a malignant disease of developing 
thymocytes that affects both children and adults. It comprises 40% of all pediatric and 10%  of 
adult ALL (Borowitz MJ 2008, Goldberg et al 2003), but is particularly prevalent as 3-4% of all 
pediatric cancers. Annually, 2000 cases of acute leukemia (ALL) are diagnosed in children in the 
US with a peak incidence at age 4, though the peak age for T-ALL in particular is during the early 
teenage years (Pui and Evans 2006). A clinical presentation including a mediastinal mass is 
classic for T-ALL, but some children also present with pallor, fatigue, fever and subcutaneous 
bleeds which is largely caused by the replacement of normal blood cells in the bone marrow by 
lymphoblasts. A life-threatening complication can arise from airway obstruction secondary to 
massive increase in the size of the thymus, or from organ failure caused by tumor lysis syndrome.  
Over the past 50 years leukemia treatment has become increasingly efficient. In the span 
from the pioneering studies by Emil Frei and colleagues (Frei et al 1965) to modern-day multi-
agent chemotherapy survival of patients with leukemia has improved from single digits to 80% 
(Silverman and Sallan 2003). Historically, though, a diagnosis of T-ALL has carried a 
significantly worse prognosis, with pediatric cure rates of only 70% (Pui and Evans 1998) and 
adult survival <40% (Larson et al 1998, Takeuchi et al 2002). While a recent review of patients 
with T-ALL treated at the Dana Farber Cancer Institute (DFCI) found that the use of modern 
treatment protocols caused leukemia remission in as great a percentage of T-ALL patients as B-
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progenitor patients the patients with T-ALL remained at increased risk for therapeutic 
complications, including induction failure, early relapse, and isolated CNS relapse (Goldberg et al 
2003). For these reasons, our current efforts are focused on devising more targeted therapies that 
improve treatment efficacy and limit side effects. In order to achieve this goal, we need to have a 
better understanding of the molecular mechanisms underlying T cell leukemia.  
There are significant similarities between T-ALL and T-cell lymphomas. Indeed, many 
clinical oncologists believe that these two entities represent a range of the same disease (Jaffe et 
al 2001). This often results in clinically treating the two diseases in the same way. While an 
understanding of the exact molecular differences between these two diseases remains to be 
resolved on an individual basis, I will use the term T-ALL to refer to the range of pathology 
encountered in this project.  
 
Pathogenesis of leukemia 
The two main mechanisms for leukemogenesis are over-expression of a proto-oncogene 
and defect in a tumor suppressor (or a combination of the two). Over-expression of proto-
oncogenes can be caused by chromosomal translocations resulting in activation of a gene that 
normally is either quiescent or controlled in normal lymphocytes (Rowley 1998). Mis-expression 
of genes in the absence of karyotypic changes is caused either by microscopic 
deletions/chromosomal rearrangements or presumably by activation of an aberrant pathway by 
other mechanisms. A frequent mechanism of translocation-induced T-ALL is the juxtaposition of 
a transcription factor or signal transduction molecule with enhancers near the TCR alpha/delta 
chain locus (TCRα/δ) on human chromosome 14 or the TCRβ locus on chromosome 7. In a 
retroviral insertion screen in mice, upregulation of divergent classes of genes caused leukemia 
(Suzuki et al 2002). These include transcription factors, signaling molecules, cell cycle regulators, 
but also structural proteins and RNA processing proteins that had previously not been identified 
as proto-oncogenes. In all these cases the mutation caused a dominant phenotype.  
  
3 
Defective expression of tumor suppressors has also been shown to cause leukemia. Here 
the mutation operates as a recessive trait. One allele is inherited from healthy parents; the other 
allele is lost (loss of heterozygosity, LOH) either physically (deletion), by inactivating point 
mutation, or by epigenetic silencing (Linggi et al 2002, Peng et al 2010, Sternik et al 1998). 
Aberrant promoter methylation has emerged as a complementary mechanism in the malignant 
transformation of cells, including lymphoblasts (Baylin 2005). The methylation status of some 
genes has also been associated with specific translocations (Baylin and Chen 2005, Garcia-
Manero et al 2002, Nakamura et al 1999) with clinical presentation and molecular characteristics 
(Zheng 2004), and with clinical outcome (Roman et al 2001).  
There is convincing epidemiologic evidence that a gene purturbation in acute leukemia 
involving a at least one transcription factor (such as CBF and RARα) is necessary for the disease 
phenotype (Gilliland 2001). There is equally compelling evidence that these mutations are not 
sufficient to cause acute leukemia, and additional mutations are required, especially in the case of 
diseases with long latency (Gilliland and Tsokos 2001). Regardless of the individual lesions, it 
appears that two events have to happen in the same cell. A hypothesis that unites these 
observations is known as the “two-hit model” of leukemogenesis where acute leukemia is caused 
by two classes of mutations. Class I mutations confer a proliferative and survival advantage to 
cells but do not affect hematopoietic differentiation. Class II mutations, in contrast, serve 
primarily to impair hematopoietic differentiation and have modest effects on proliferation and 
survival (Gilliland 2001). 
 
A current understanding of T-ALL 
In T-ALL chromosomal break points often involve the TCRβ  enhancer (7q34) or the 
TCRα/δ enhancer (14q11), both of which are highly active in committed T cell progenitors, 
resulting in the deregulated expression of transcription factor genes located at the break point on 
reciprocal chromosomes (Ferrando and Look 2000). The transcription factors affected by these 
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molecular changes include basic helix-loop-helix (bHLH) family members like TAL1 (Begley et 
al 1989) and MYC (McKeithan et al 1986), LIM-only domain (LMO) genes LMO1 and LMO2 
(McGuire et al 1992), and the orphan homeobox genes HOX11 and HOX11L2 (Dube et al 1991).   
TAL1 is a master regulatory protein active during early hematopoietic development, and 
is required for the generation of all blood lineages (Shivdasani et al 1995).  This bHLH 
transcription factor binds to DNA by forming heterodimers with other bHLH factors such as E2A 
(Baer 1993). Mice lacking E2A develop T cell leukemia (Bain et al 1997) and Tal1 transgenic 
mice on an E2A- background also show accelerated development of the disease (O'Neil et al 
2004). The LIM-only domain genes encode proteins that contain duplicated cysteine-rich LIM 
domains involved in protein-protein interaction. LMO1 and LMO2 can be activated by 
translocation to the TCR enhancer loci, or in the case of LMO2, by deletions that remove the 
negative regulator of LMO2 expression (McGuire et al 1992). Homozygous disruption of Lmo2 in 
mice causes the same phenotype as described above for Tal1-deficient mice, suggesting that these 
two proteins interact in the same pathway and over-expression of either of these genes 
transgenically in mouse thymocytes leads to T cell lymphomas (McGuire et al 1992). The 
interaction of these two proteins was further confirmed when it was shown that LMO2 forms a 
novel DNA-binding complex with GATA-1, TAL1 and E2A, and the LIM-binding protein 
Ldb1/NLI (Wadman et al 1997). HOX11 was originally isolated from the site of the recurrent 
t(10;14)(q24;q11) translocation in T-ALL (Dube et al 1991). Similar to other HOX genes, HOX11 
plays an important role in embryonic development, and functions as a master transcriptional 
regulator necessary for the creation of the spleen (Roberts et al 1994). 
The mammalian NOTCH proteins are heterodimeric transmembrane receptors that 
control cell proliferation, apoptosis and cell fate during the development of diverse cellular 
lineages (Radtke et al 2004) The protein is a transmembrane receptor whose activation occurs 
when ligands of the Delta-Serrate-Lag2 (DSL) family bind to one of its heterodimeric subunits 
and initiate a cascade of proteolytic cleavages resulting in NOTCH1 translocation to the nucleus 
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and formation of a large transcriptional activation complex (Logeat et al 1998, Sanchez-Irizarry et 
al 2004). A recent study has shown that activated NOTCH signaling is found in over 50% of 
human T-ALL patient samples and cell lines (Weng et al 2004). The mutations were found in all 
subtypes of T-ALL and are concentrated in two regions of the NOTCH1 protein. Missense 
mutations in the heterodimerization domain activate NOTCH signaling by altering the interaction 
between the transmembrane subunit and the inhibitory extracellular subunit of NOTCH1 
(Malecki et al 2006). Frameshift and point mutations in the C-terminal region of the NOTCH1 
gene were also observed, which caused a deletion of the PEST domain, preventing NOTCH1 
protein from being targeted for degradation by the proteosome. Similar activating mutations were 
also found in mouse models of T-ALL, demonstrating a conserved role for NOTCH in T-ALL 
and providing a model in which to test therapeutics.  
 
Zebrafish as a cancer model system 
 Studies in invertebrate organisms such as flies and worms have investigated the 
development of abnormal cellular proliferation, but what we recognize clinically and 
pathologically as cancer is present almost exclusively in vertebrates. This means that to truly 
understand the formation, growth and spread of malignancy, vertebrate models are essential. 
Using mice as model organisms, we have greatly enhanced our understanding of the mechanisms 
of human carcinogenesis and cancer progression. Zebrafish, a vertebrate model system, combines 
the advantages of invertebrate organisms with those of mammalian models: large clutch sizes and 
the ability to visualize biologic processes in vivo aid in the identification of molecular genetic 
pathways involved in organ development and homeostasis, whereas the histology of normal tissue 
and cancers is highly similar to that of mouse and human samples. 
The zebrafish is a unique system in which to model cancers of the immune system. 
Although more than 450 million years separate the last common ancestor of zebrafish and 
humans, the immune system in zebrafish parallels its human counterpart (Meeker and Trede 
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2008, Trede et al 2004). In addition, the biology of cancer also appears to be very similar in these 
two organisms (Amatruda and Zon 1999, Ignatius and Langenau 2009, Stoletov and Klemke 
2008). Cancer commonly occurs in fish in the wild, and studies have shown that exposure to 
carcinogens in water can cause a wide variety of both benign and malignant tumors in virtually all 
organs of jawed fishes (teleosts) with histology that frequently closely resembles human tumors 
(Hawkins et al 1985).  
 
The zebrafish adaptive immune system parallels that of humans 
In general, the zebrafish adaptive  immune system has proven to be remarkably similar to 
that of humans (Traver et al 2003, Trede et al 2004). The evolution of the adaptive immune 
system coincided with the emergence of the jawed vertebrates, far in advance of the divergence of 
fish from other vertebrates (Du Pasquier 2004, Laird et al 2000). Therefore, the adaptive and 
innate branches of the immune system are remarkably conserved across teleosts and other 
vertebrates, including mammals. 
The adaptive immune response, composed of antibodies, specific cellular populations and 
secondary lymphoid organs such as the bone marrow, thymus, lymph nodes and spleen, is 
responsible for specific responses to specific pathogens. The thymus, which plays a major role in 
adaptive immunity, may have its earliest equivalent in the jawless lamprey (Amemiya et al 2007, 
Ardavin and Zapata 1988), but evolution of the true structural and functional equivalent of the 
thymus in higher vertebrates coincides with the development of the jaw, and teleost fishes are the 
first jawed vertebrates. Thymic organogenesis and lymphoid development are highly conserved 
from teleosts, including zebrafish, to mammals.  
Thymic development. The overall process of thymic development as well as its separation 
into a cortex and medulla are well conserved through vertebrate evolution (Manley 2000). Both 
the ectoderm and the endoderm have been shown to be essential for the formation of functioning 
thymic organs in both teleosts and mammals. There are, however, interesting differences in 
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thymic development between fishes and humans. The most obvious is that the thymus in 
zebrafish remains as two distinct organs throughout development, whereas mammals have a 
single thymus (Trede et al 2004). Functionally, the main differences between zebrafish and 
mammals concern the timing of thymic development. In zebrafish, thymic development initiates 
at about 48 hours post fertilization (hpf), and a thymic rudiment is formed by 60 hpf, but 
separation into cortical and medullary compartments of the organ is not fully discernable in its 
conical shape until 2-3 weeks of age (Lam et al 2002) In the mouse, the interaction between 
thymic epithelial cells (TECs) and thymocytes, required for maturation of TECs and separation 
into medullary and cortical compartments, occurs as early as E15, and is complete shortly after 
birth (Snodgrass et al 1985). In humans, the thymus rudiment is colonized during the 6th week of 
gestation (Klein and Hořejší 1997) 
Lymphocyte diversity. Antigen receptor genes exist in the germline in a “split” 
configuration and are assembled in developing B and T lymphocytes by V(D)J recombination. 
This site-specific recombination reaction is initiated by a complex containing the RAG1 and 
RAG2 proteins and completed by general DNA repair factors. RAG1 and RAG2, like the adaptive 
immune system itself, are found exclusively in jawed vertebrates, and are thought to have entered 
the vertebrate genome by horizontal transmission as components of a transposable element. These 
clusters of functional gene segments are organized into three gene clusters located on different 
chromosomes. In zebrafish rag gene expression was first detected in the thymus at 4 days post 
fertilization (dpf) and in the pronephros at 21 dpf by RNA in situ hybridization (Willett et al 
1999), although we have observed rag expression in the pronephros as early as 8 dpf 
(unpublished). 
T cell development. The first detectable T cells in the zebrafish thymus by gene 
expression studies occur at 72 hpf at the same time the embryo hatches from its protective 
chorion. Immunocompetence, though, as measured by humoral response to T-dependent and –
independent antigens, is not reached until 4-6 weeks after hatching. The environment for T cell 
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development in the zebrafish is different than the T cell population of the mouse thymus of the 
same developmental stage (E15) which has the advantage of a protective intrauterine environment 
for the first three weeks of life, with peripheral T cells appearing at about 7 days after birth (Lam 
et al 2002). Genomic organization of the zebrafish TCRα  locus has been characterized and many 
gene segments sequenced, revealing over 15 Vα  genes. TCRβ and γ constant regions have also 
been recently identified by gene expression studies (Meeker et al 2010). This general 
conservation suggests that the overarching diversity of rearranged TCR genes in zebrafish has the 
potential to be very high.  
 
Tools for zebrafish as an experimental system 
Large-scale genetic screens. Traditionally, the popularity of zebrafish as a model 
organism was based in the advantages it offered for studying vertebrate development. The 
zebrafish also has many properties that make it an ideal organism for systematic mutational 
approaches. It has a short generation time of 2-4 months, can be kept at high density in a small 
space with relatively little maintenance, resulting in reduced cost. With the development of 
efficient strategies to raise and maintain large numbers of independent zebrafish lines, it has 
become feasible to perform large-scale mutational screens. One pair of fish can sire an average of 
200 progeny at weekly intervals, which greatly facilitates collection of large numbers of mutant 
individuals for mapping and genetic analysis. Use of zebrafish facilitates both screens employing 
standard crossing schemes to produce homozygous mutant embryos (classic F3 screens), and 
those that use gynogentic diploid embryos derived from fertilizing eggs in vitro using UV-
inactivated sperm (early pressure screens). Classic F3 screens breed mutagenized males with 
wild-type females, and their offspring (F1) are interbred to yield heterzygotic carriers of the 
mutations (F2) (Driever et al 1996, Haffter et al 1996). The phenotypes of the recessive mutations 
are revealed in F3 generation offspring, in which the mutated genes are driven to homozygosity. 
These F3 fish can be examined at various stages of development for signs of abnormality. 
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 Early pressure (EP) screens use embryos derived from in vitro fertilized eggs using UV-
inactivated sperm immediately followed by inhibition of the second meiotic division by 
application of high atmospheric pressure (6-8000 lbs/sq inch) to break mitotic spindles. Here, 
both alleles of a gene are derived from either the wild type or mutated version of the meiotically 
duplicated maternal sister chromatids resulting in an animal homozygous for a particular locus. 
The advantage of this approach is that mutations that are heterozygous in the F1 female are 
“homozygosed,” revealing mutant phenotypes immediately in the F2 generation. In addition, the 
resulting offspring are often viable and fertile. Viability and fertility of affected individuals are of 
pivotal importance for detection of immunodeficiencies or lymphoproliferative diseases because 
zebrafish lymphopoiesis occurs relatively late compared to other developmental processes. This 
technique makes it possible to use genetic screens for immunodeficiencies or lymphoproliferation 
beginning at 6 dpf, when T cell progenitors have typically colonized the thymus (Trede et al 
2008) and continuing into adulthood (Frazer et al 2009) when the immune system, and the 
animal, reaches maturity as discussed above.  
Transgenic animals. While the genetics underlying the development of the zebrafish 
lymphoid system has been an active area of investigation, functional studies to facilitate 
characterization of different lymphoid cell populations have been hampered by the lack of tools. 
In particular, there is a dearth of antibodies directed to surface receptors that are relevant to the 
immune system.  More recently transgenic technology and lineage-restricted gene promoters have 
been used to drive the expression of fluorophores in specific blood cell lineages. Transgenic 
zebrafish lines that express genetic markers controlled by both rag1 and rag2 promoters (Jessen 
et al 2001, Long et al 1997, Meng et al 1997) have been instrumental in tracking immature T 
cells,  but such experiments were restricted to immature rag+ cells, and could not be used to track 
mature T or B cells.  
In 2004, Langenau et al. created a transgenic zebrafish in which the T-cell specific 
tyrosine kinase (p56lck) gene promoter regulated GFP expression in lymphocytes (Figure 1.1). 
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This particular line allows for in vivo tracking of T cell homing and accumulation in tissues, and 
is amenable to forward genetic screens for mutants causing immunodeficiencies, autoimmune 
disease, or malignancy. Use of this line has shown that lck mRNA expression is first detected in T 
cells located in the bilateral thymic lobes by 3dpf, greatly increases in numbers by 7dpf ,  and, in 
addition, is located in cells throughout the thymus, not just cortex or medulla. Additionally, this 
study confirmed that lymphocytes home to the kidney, spleen, gastrointestinal lining, gills and 
olfactory epithelium (Figure 1.2).  Mature T cells were shown to reside in the kidney marrow, and 
the thymus was demonstrated to harbor two distinct subpopulations of T cells at various stages of 
development (Figure 1.3). Varying in size, these thymocyte populations suggest that zebrafish 
lymphocytes likely change size as they mature, agreeing with the correlation between lymphocyte 
size and maturational stage of development described previously in mammals (Langenau et al 
2004). The advent of similar transgenic lines, expressing fluorophores under the control of cell-
specific promoters, allows us to marry the benefits of large-scale genetic screens in zebrafish with 
the relatively simple identification of mutants by visual inspection under fluorescence 
microscopy. In many cases, these screens are feasibly not only in transparent larvae, but also in 
adults.  
Transplantation immunology. Efficient hematopoietic cell transplantation in mammals 
requires the ablation of the host immune system to prevent rejection and to create a niche space 
for engraftment of donor cells in the bone marrow. In mouse and humans, one way to achieve this 
ablation is by using a dose of γ-irradiation that destroys the hematopoietic system to a point 
where it cannot recover spontaneously, so that bone marrow infusion from a donor is required for 
survival. Recent studies have shown that despite the divergence of teleosts and mammals nearly 
450 million years ago, a minimum lethal dose of γ-irradiation leads to hematopoietic ablation and 
eventually death from bone marrow failure in zebrafish (Traver et al 2004). Recent studies have 
also shown that lymphocytes derived from an adult zebrafish thymus homed to the thymus when 
injected into a 2-day-old embryo (Langenau et al 2004). Twenty-four hours after intracardiac 
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injection these cells were also found in the circulation. Transplantation experiments in adult, 
sublethally irradiated, fish have also confirmed that GFP-labeled T cells can home to the thymus, 
kidney, and peripheral sites where T cells are found physiologically (Langenau et al 2004). The 
knowledge provided by these transplantation experiments now allows us to isolate cells of 
interest using flow cytometry and introduce these cells into irradiated recipients to test autonomy 
of mutant gene function, and analyze engraftment potential of hematopoietic cell lineages in 
zebrafish.  
 
Previous models of T cell acute leukemia in zebrafish 
The first zebrafish ALL model utilized the zebrafish promoter to drive expression of 
murine MYC to induce disease (Langenau et al 2003). Because a GFP reporter construct was also 
present, the authors could determine with in vivo fluorescence microscopy that essentially all fish 
with rag2 promoter-driven lymphoid expression of MYC developed T-ALL, with a mean latency 
of about 50 days. When this same construct was stably incorporated in the germ-line, again all 
fish acquired T-ALL, now with a mean latency of 32 days (Langenau et al 2005). The near-100% 
penetrance and short latency both support that because murine MYC is a potent oncogene in this 
system only few acquired mutations are required for leukemic transformation. However, the 
transgenic line could not be maintained, as fish carrying the transgene typically die of disease 
prior to reaching sexual maturity. Another potentially salient point is that the MYC-driven D. 
rerio model best represents only one human T-ALL type, the TAL1+ late cortical thymocyte 
subgroup (Ferrando et al 2002, Ferrando and Look 2003, Palomero et al 2006). 
A modified strategy, where Cre recombinase was used to conditionally activate murine 
Myc, circumvents the difficulty in propagating the transgenic line. However, when Cre RNA was 
injected into one-cell embryos of stably-transgenic MYC fish (to remove ‘floxed’ transcription 
stop sites preceding Myc), T-ALL penetrance dropped to 6%, suggesting inefficient 
microinjection, incomplete Cre-mediated excision, or both (Langenau et al 2005).  Compound 
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transgenic fish with heat-shock inducible-Cre and loxP-Stop-loxP-MYC were a further 
refinement, where T-ALL rates of up to 81% could be achieved (Feng et al 2007). Again, this 
very high incidence attests to the oncogenic potency of murine MYC in D. rerio, and poises this 
system for use in suppressor screens as well. Clearly, this series of studies set an important 
precedent, establishing that mammalian genes can be similarly oncogenic in zebrafish lymphoid 
cancers.  
A second transgenic zebrafish T-ALL model expressed a truncated and constitutively-
active form of human NOTCH1 protein, targeted to lymphocytes through the use of the zebrafish 
rag2 promoter (Chen et al 2007). Fish from this line display 40% penetrance, but have relatively 
long latency (disease begins at 11 months).  Leukemias in this model are oligoclonal, and express 
a range of Notch1 target genes such as her6 (the zebrafish orthologue of HES1) and her9. 
Although the mMyc models show an overexpression of the known T-ALL oncogenes tal1/scl and 
lmo2, the human NOTCH1-induced T cell leukemias lack appreciable expression levels of these 
oncogenes implying that the pathogenic mechanism of disease in these two models is distinct.  
A final example of D. rerio ALL models used the oncogenic human TEL-AML1 fusion 
gene. These lines utilized either the ubiquitous Xenopus elongation factor 1a (XEF), zebrafish β-
actin (ZBA) promoters, or a lymphoid-specific zebrafish rag2 promoter (Sabaawy et al 2006). 
The expression of human TEL-AML1 from the ubiquitous XEF and ZBA promoters led to low 
penetrance (3%) of B cell acute lymphoblastic leukemia, with a latency of 8-12 months. No fish 
expressing rag2-driven TEL-AML1 developed leukemia during the 36-month observation period, 
leading the authors to conclude that TEL-AML1 typically acts in a B lymphocyte precursor stage 
prior to Rag expression, at least in the human version of this disease. This model mimics 
childhood CD10+ pre-B ALL, and its long latency and low penetrance make it well suited for 





Goal of the dissertation 
T-ALL is a particularly heterogeneous and while many pediatric malignancies have 
characteristic translocations, most T lymphocyte-derived diseases carry no cytogenetic hallmark. 
Lacking these informative lesions, insight into their molecular pathogenesis is incomplete. An 
increased understanding of the molecular mechanisms characterizing the pathogenesis of T-ALL 
will reveal critical targets, and may allow for the formulation of more specific and effective 
therapies. Therefore, the discovery of heretofore-unrecognized lymphocyte oncogenes and tumor 
suppressors is of potentially profound significance to both clinical medicine and scientific 
understanding. Thus, my dissertation work has sought to address several aspects of T-ALL 
pathogenesis using the zebrafish. 
1. Can the development of heritable zebrafish T-ALL model loyally recapitulate the 
human form of the disease?  
Previous published models of zebrafish T-ALL rely on transgenic, known 
oncogenes to drive disease. In Chapter 2, I discuss a way in which we pioneered 
a forward genetic screen to identify new, hereditary models of T-ALL in the 
zebrafish. These models are driven by as-yet unknown mutations. 
2. Can nonhuman models of T-ALL be used to identify leukemogenic factors in 
humans?  
There are many genetic studies that may be useful in further understanding the 
development of T-ALL, and many molecular genetic studies that can be done to 
identify disease targets. These types of analyses, and other large-scale therapeutic 
screens cannot be done in humans, or even mouse models. In Chapter 3 of my 
dissertation, I discuss how zebrafish models of acute leukemias are uniquely 
suited to help in these efforts. 
3. What is the underlying mechanism of disease in otg fish? 
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Chapter 4 of my dissertation details how we determined that otg fish are resistant 
to irradiation-induced apoptosis, and how we then interrogated the apoptosis 
pathway to determine where functionality was lost in this mutant. We studied 
each step in this cascade, including double strand break repair, p53 effectors, and 
mitochondrial activation, to determine that otg mutation results in a block at the 
level of the mitochondria, preventing irradiation-induced apoptosis.  
4. Can copy number analysis in zebrafish leukemia help identify new candidate 
genes that may be responsible for oncogenesis or aggressiveness in primary 
human T-ALLs?  
In Chapter 5 of my dissertation I discuss using array comparative genomic 
hybridization (aCGH) on zebrafish primary and serially passaged T-ALLs to 
determine genes that may contribute to transformation and oncogenesis. I also 
discuss the use of transplantation techniques as a proxy for relapsed human 
disease, and a number of genes that we have identified which are altered in both 
zebrafish and human T-ALLs, suggesting links between these candidate genes 
and T-ALL that have been conserved throughout evolution.  
 
References  
Amatruda JF, Zon LI (1999). Dissecting hematopoiesis and disease using the zebrafish. Dev Biol 
216: 1-15. 
 
Amemiya CT, Saha NR, Zapata A (2007). Evolution and development of immunological 
structures in the lamprey. Curr Opin Immunol 19: 535-541. 
 
Ardavin CF, Zapata A (1988). The pharyngeal lymphoid tissue of lampreys. A morpho-functional 
equivalent of the vertebrate thymus? Thymus 11: 59-65. 
 
Baer R (1993). TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in 
T cell acute leukaemia. Semin Cancer Biol 4: 341-347. 
 
Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL et al. (1997). E2A 
deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-




Baylin SB (2005). DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 Suppl 
1: S4-11. 
 
Baylin SB, Chen WY (2005). Aberrant gene silencing in tumor progression: implications for 
control of cancer. Cold Spring Harb Symp Quant Biol 70: 427-433. 
 
Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J et al. (1989). 
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen 
receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc 
Natl Acad Sci U S A 86: 2031-2035. 
 
Borowitz MJ CJ (2008). T-lymphoblastic leukaemia/lymphoma. In: Swerdlow SH, Campos E, 
Harris, N.L., Jaffe, E.F., Pileri, S.A., Stein, H., Thiele J, Vardiman, J.W (ed). WHO Classification 
of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon. pp 176-178. 
 
Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD (2007). NOTCH1-induced T-cell 
leukemia in transgenic zebrafish. Leukemia 21: 462-471. 
 
Driever W, Solnica-Krezel L, Schier AF, Neuhauss SC, Malicki J, Stemple DL et al. (1996). A 
genetic screen for mutations affecting embryogenesis in zebrafish. Development 123: 37-46. 
 
Du Pasquier L (2004). Speculations on the origin of the vertebrate immune system. Immunol Lett 
92: 3-9. 
 
Dube ID, Kamel-Reid S, Yuan CC, Lu M, Wu X, Corpus G et al. (1991). A novel human 
homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal 
translocation t(10;14). Blood 78: 2996-3003. 
 
Feng H, Langenau DM, Madge JA, Quinkertz A, Gutierrez A, Neuberg DS et al. (2007). Heat-
shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic 
zebrafish. Br J Haematol 138: 169-175. 
 
Ferrando AA, Look AT (2000). Clinical implications of recurring chromosomal and associated 
molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol 37: 381-395. 
 
Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. (2002). Gene 
expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. 
Cancer Cell 1: 75-87. 
 
Ferrando AA, Look AT (2003). Gene expression profiling in T-cell acute lymphoblastic 
leukemia. Semin Hematol 40: 274-280. 
 
Frazer JK, Meeker ND, Rudner L, Bradley DF, Smith AC, Demarest B et al. (2009). Heritable T-
cell malignancy models established in a zebrafish phenotypic screen. Leukemia 23: 1825-1835. 
 
Frei E, 3rd, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J et al. (1965). The 
effectiveness of combinations of antileukemic agents in inducing and maintaining remission in 




Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM et al. (2002). 
DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic 
leukemia. Clin Cancer Res 8: 2217-2224. 
 
Gilliland DG (2001). Hematologic malignancies. Curr Opin Hematol 8: 189-191. 
 
Gilliland WR, Tsokos GC (2001). The clinical spectrum of anti-insulin receptor antibodies and 
autoimmune disease. J Clin Rheumatol 7: 361-362. 
 
Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L et al. (2003). 
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute 
lymphoblastic leukemia consortium experience. J Clin Oncol 21: 3616-3622. 
 
Haffter P, Granato M, Brand M, Mullins MC, Hammerschmidt M, Kane DA et al. (1996). The 
identification of genes with unique and essential functions in the development of the zebrafish, 
Danio rerio. Development 123: 1-36. 
 
Hawkins WE, Overstreet RM, Fournie JW, Walker WW (1985). Development of aquarium fish 
models for environmental carcinogenesis: tumor induction in seven species. J Appl Toxicol 5: 
261-264. 
 
Ignatius MS, Langenau DM (2009). Zebrafish as a model for cancer self-renewal. Zebrafish 6: 
377-387. 
 
Jaffe E, Harris N, Stein H, Vardiman J (2001). Pathology and genetics of tumours of 
haematopoietic and lymphoid tissues. World Health Organization classification of tumours. 
IARC Press: Lyon. 
 
Jessen JR, Jessen TN, Vogel SS, Lin S (2001). Concurrent expression of recombination activating 
genes 1 and 2 in zebrafish olfactory sensory neurons. Genesis 29: 156-162. 
 
Klein J, Hořejší V (1997). Immunology Blackwell Science: Oxford. 
 
Laird DJ, De Tomaso AW, Cooper MD, Weissman IL (2000). 50 million years of chordate 
evolution: seeking the origins of adaptive immunity. Proc Natl Acad Sci U S A 97: 6924-6926. 
 
Lam SH, Chua HL, Gong Z, Wen Z, Lam TJ, Sin YM (2002). Morphologic transformation of the 
thymus in developing zebrafish. Dev Dyn 225: 87-94. 
 
Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP et al. (2003). Myc-induced 
T cell leukemia in transgenic zebrafish. Science 299: 887-890. 
 
Langenau DM, Ferrando AA, Traver D, Kutok JL, Hezel JP, Kanki JP et al. (2004). In vivo 
tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc Natl Acad 
Sci U S A 101: 7369-7374. 
 
Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT (2005). Cre/lox-regulated 
transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. 




Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ et al. (1998). A randomized 
controlled trial of filgrastim during remission induction and consolidation chemotherapy for 
adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92: 1556-1564. 
 
Linggi B, Muller-Tidow C, van de Locht L, Hu M, Nip J, Serve H et al. (2002). The t(8;21) 
fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor 
suppressor in acute myeloid leukemia. Nature medicine 8: 743-750. 
 
Logeat F, Bessia C, Brou C, LeBail O, Jarriault S, Seidah NG et al. (1998). The Notch1 receptor 
is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci U S A 95: 8108-8112. 
 
Long Q, Meng A, Wang H, Jessen JR, Farrell MJ, Lin S (1997). GATA-1 expression pattern can 
be recapitulated in living transgenic zebrafish using GFP reporter gene. Development 124: 4105-
4111. 
 
Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, Aster JC et al. (2006). 
Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least 
two distinct mechanistic classes. Mol Cell Biol 26: 4642-4651. 
 
Manley NR (2000). Thymus organogenesis and molecular mechanisms of thymic epithelial cell 
differentiation. Semin Immunol 12: 421-428. 
 
McGuire EA, Rintoul CE, Sclar GM, Korsmeyer SJ (1992). Thymic overexpression of Ttg-1 in 
transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma. Mol Cell Biol 12: 
4186-4196. 
 
McKeithan TW, Shima EA, Le Beau MM, Minowada J, Rowley JD, Diaz MO (1986). Molecular 
cloning of the breakpoint junction of a human chromosomal 8;14 translocation involving the T-
cell receptor alpha-chain gene and sequences on the 3' side of MYC. Proc Natl Acad Sci U S A 
83: 6636-6640. 
 
Meeker ND, Trede NS (2008). Immunology and zebrafish: spawning new models of human 
disease. Dev Comp Immunol 32: 745-757. 
 
Meeker ND, Smith AC, Frazer JK, Bradley DF, Rudner LA, Love C et al. (2010). 
Characterization of the zebrafish T cell receptor beta locus. Immunogenetics 62: 23-29. 
 
Meng A, Tang H, Ong BA, Farrell MJ, Lin S (1997). Promoter analysis in living zebrafish 
embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl 
Acad Sci U S A 94: 6267-6272. 
 
Nakamura M, Sugita K, Inukai T, Goi K, Iijima K, Tezuka T et al. (1999). p16/MTS1/INK4A 
gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia 
with 11q23 translocation. Leukemia 13: 884-890. 
 
O'Neil J, Shank J, Cusson N, Murre C, Kelliher M (2004). TAL1/SCL induces leukemia by 
inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5: 587-596. 
 
Palomero T, Odom DT, O'Neil J, Ferrando AA, Margolin A, Neuberg DS et al. (2006). 
Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic 




Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG et al. (2010). PTEN is a tumor 
suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115: 626-635. 
 
Pui CH, Evans WE (1998). Acute lymphoblastic leukemia. N Engl J Med 339: 605-615. 
 
Pui CH, Evans WE (2006). Treatment of acute lymphoblastic leukemia. N Engl J Med 354: 166-
178. 
 
Radtke F, Wilson A, MacDonald HR (2004). Notch signaling in T- and B-cell development. Curr 
Opin Immunol 16: 174-179. 
 
Roberts CW, Shutter JR, Korsmeyer SJ (1994). Hox11 controls the genesis of the spleen. Nature 
368: 747-749. 
 
Roman J, Castillejo JA, Jimenez A, Bornstein R, Gonzalez MG, del Carmen Rodriguez M et al. 
(2001). Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated 
with unfavourable clinical outcome. Br J Haematol 113: 329-338. 
 
Rowley JD (1998). The critical role of chromosome translocations in human leukemias. Annu Rev 
Genet 32: 495-519. 
 
Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD (2006). TEL-AML1 
transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci 
U S A 103: 15166-15171. 
 
Sanchez-Irizarry C, Carpenter AC, Weng AP, Pear WS, Aster JC, Blacklow SC (2004). Notch 
subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, 
respectively, on a novel domain and the LNR repeats. Mol Cell Biol 24: 9265-9273. 
 
Shivdasani RA, Mayer EL, Orkin SH (1995). Absence of blood formation in mice lacking the T-
cell leukaemia oncoprotein tal-1/SCL. Nature 373: 432-434. 
 
Silverman LB, Sallan SE (2003). Newly diagnosed childhood acute lymphoblastic leukemia: 
update on prognostic factors and treatment. Curr Opin Hematol 10: 290-296. 
 
Snodgrass HR, Kisielow P, Kiefer M, Steinmetz M, von Boehmer H (1985). Ontogeny of the T-
cell antigen receptor within the thymus. Nature 313: 592-595. 
 
Sternik G, Pittis MG, Gutierrez M, Diez RA, Sen L (1998). In acute lymphoblastic leukemia 
deletion of the tumor suppressor gene P16 is associated with abnormal interferon genes. Medicina 
(B Aires) 58: 463-468. 
 
Stoletov K, Klemke R (2008). Catch of the day: zebrafish as a human cancer model. Oncogene 
27: 4509-4520. 
 
Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. (2002). 
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in 




Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S et al. (2002). Induction therapy by 
frequent administration of doxorubicin with four other drugs, followed by intensive consolidation 
and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. 
Leukemia 16: 1259-1266. 
 
Traver D, Herbomel P, Patton EE, Murphey RD, Yoder JA, Litman GW et al. (2003). The 
zebrafish as a model organism to study development of the immune system. Adv Immunol 81: 
253-330. 
 
Traver D, Winzeler A, Stern HM, Mayhall EA, Langenau DM, Kutok JL et al. (2004). Effects of 
lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation. Blood 104: 1298-
1305. 
 
Trede NS, Langenau DM, Traver D, Look AT, Zon LI (2004). The use of zebrafish to understand 
immunity. Immunity 20: 367-379. 
 
Trede NS, Ota T, Kawasaki H, Paw BH, Katz T, Demarest B et al. (2008). Zebrafish mutants 
with disrupted early T-cell and thymus development identified in early pressure screen. Dev Dyn 
237: 2575-2584. 
 
Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A et al. (1997). The LIM-
only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which 
includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. The EMBO journal 16: 3145-3157. 
 
Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. (2004). 
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 
269-271. 
 
Willett CE, Cortes A, Zuasti A, Zapata AG (1999). Early hematopoiesis and developing 








Figure 1.1. lck::EGFP transgenic zebrafish. Diagrams of the genomic DNA sequence comprising the lck promoter (A) and the GFP construct 
(B) are shown. Enzyme digest sites used for cloning and restriction mapping of the minimal promoter are shown. lck::EGFP transgenic fish 
expressing the 5.5-kb EcoRI-NotI fragment (C) are shown at 8 dpf (D), 45 dpf (E), and 80 dpf (F). Arrowheads denote GFP-labeled cells in the 










Fig 1.2. Anti-GFP immunostaining of sectioned lck::EGFP transgenic fish. Thymus (A), kidney (B), intestinal lining (C), nasal epithelium 







Fig 1.3. FACS analysis of cells from the kidney (C,D) and thymus (G,H) lck::EGFP transgenic zebrafish. Gated populations of erythrocytes 
(red), lymphocytes (blue), granulocytes and monocytes (green), and blood cell precursors (purple) are outlined. Populations of cells within each 
gate are described as percentages of total live cells (±1 SD; n = 18 for C; and n = 8 for, D, and G,H). Cell size is represented by forward scatter 
(FSC), and granularity is represented by side scatter (SSC). GFP-positive cells in the progenitor gate in thymus samples became confined to the 
lymphoid gate upon reanalysis, confirming that GFP-labeled populations in the progenitor gate are predominately lymphoid in origin. (Modified 
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Supplemental Table 2.1. Malignant involvement of marrow and blood in srk, hlk, and otg 
mutant fish. Single cell suspensions from marrow and blood of WT and tumor-bearing mutant 
fish were analyzed by flow cytometry, with dead cell exclusion by 7-Amino-Actinomycin D (7-
AAD). WT marrows demonstrated 7.5% of viable cells to be GFP+ (SD = standard deviation). 
Defining abnormal as >3 SD above the WT mean, 6/6 srk, 4/7 hlk, and 2/6 otg fish with tumors 
showed marrow infiltration (Marrow Affected Individuals columns), with mean values of 69.4%, 
50.3%, and 38.2% of total cells, respectively. Using these same criteria, 4/6 srk, 4/12 hlk, and 2/8 
otg fish with thymic tumors demonstrated pathologic blood involvement (Peripheral Blood 
Affected Individuals columns), with mean values of 18.8%, 10.8%, and 40.5% of total cells being 
GFP+.  WT lck::EGFP fish have only rare GFP+ cells in peripheral circulation (0.35 +/- 0.6%). 














WIK lck::EGFP  . . . ATCGTGGCAC CCCTGTCCCCCG 
CTGTCTGGAC . 
. . 5 (17.9) 
(n=28) . . . ATCGTGGCAC CCCTGTCCCCCG 
TCTGTACCCT . 
. . 2 (7.1) 
 . . . ATCGTGGCAC CCCTGTCC 
TTGTACCCTT . 
. . 1 (3.6) 
 . . . ATCGTGGCAC CCCTGTCCCCCG 
ATTATTAGAC . 
. . 1 (3.6) 
 . . . ACGTCGAATG CCCTGTCCCCCG 
CTAGTTCGGA 
. . . 1 (3.6) 
 . . . CGACGATCTT      CTGTCCCCC 
CAGAGTCAGG. 
. .  5 (17.9) 
 . . . ACACGTCGAT    CCTGTCC 
ATGGAGACCA 
. . . 2 (7.1) 
 . . . GACACGTCGG         TGTCCC 
ATGTGACCAC. 
. .  3 (10.7) 
 . . . ACGGTGTTCG              TCC 
TTGTGACGGT . 
. . 3 (10.7) 
 . . . TAACACGTCG           GTC 
AGGTTGGTGA 
. . . 1 (3.6) 
 . . . ACGCATAATA           GTC 
TTGTGACCGT . 
. . 3 (10.7) 
 . . . AGACGCGAAG         CTGT 
TTGTGACGGT. 
. .  1 (3.6) 
hlk (n=15) . . . GACACGTCGA CCCTG 
CTTGTGACCG . 
. . 9 (60.0) 
 . . . AGTCACTCAC           GTC 
TGTCTGGACG 
. . .  6 (40.0) 
srk (n=11) . . . ACACGTCGTG                C 
ATTAGAGTCA 
. . . 9 (81.8) 
 . . . CACGGTGTTC           GTCC 
TTGTGACGGT . 
. . 1 (9.1) 
 . . . AAACACGGCG         TGTCCCCCG 
GTTAATAGTT . 
. . 1 (9.1) 
otg (n=15) . . . GCGTCGTAGA         TG 
TGTTTGAGTT . 
. . 14 (93.3) 
 . . . AGGGAGTTTT           T 
ATATTAAGGG 
. . . 1 (6.7) 
 
Supplemental Table 2.2 VDJ alignments of 5’RACE products. Sequences used to compile 
Figure 5 are shown. Last 10 bp of each Vb1 gene and first 10 bp of each Jb1 gene segment are 
aligned. Intermediary sequences, deriving from the Db1 gene segment and non-templated N-
segment additions/deletions that accompany recombination are listed in the Diversity column. 











Gene Forward Primer Reverse Primer 
lck 5’-agatgaatggtgtgaccagtgta-3’ 5’-gatcctgtagtgcttgatgatgt-3’ 
rag2 5’-accctctcgtttgatccgtctcc-3’ 5’-attcatcctcctcatcttcctcgttat-3’ 
trac 5’-tctgctgtgtattactgtgctctga-3’ 5’-gctcatccacgctttgaaagtcacca-3’ 
cd4 5’-tccctggtcggtcttaaatgaaac-3’ 5’-cagatgaggcggagacttgtgat-3’ 
cd8a 5’-tccccaccattacaaaaggcaacc-3’ 5’-tttagcgtagaaacataaaagtgaacagc-3’ 
mpx 5’-ccagaaccagtgagcctgagacacg-3’ 5’-gtgggttcttccgattgttgcaga-3’ 
ef1a 5’-ccaacttcaacgctcaggtcat-3’ 5’-agtagagtgcccaggtttagaga-3’ 
 
RT-PCR conditions: 
55°C annealing temperatures were used for lck and ef1a; 58°C for rag2, trac, cd4, and cd8a; and 
59°C for mpx. PCR reactions were 35 cycles for rag2, trac, and ef1a; 38 cycles for lck, cd4, cd8a, 
and mpx.  
5’ RACE primers (from tcrb1 constant region exon 3): 
 outer primer: 5'-tccgctcttagcaatggtcacgccata-3' 
  









Supplemental Figure 2.1. Tumor progression in srk, hlk, and otg fish. Fish were serially assayed by fluorescence microscopy for thymic 
expression lck::EGFP and the development of GFP+ tumors. Serial images of individual tumor-bearing fish from each mutant line are shown. 
Images were obtained at the listed age in days (d), displaying the rapid growth of tumors. Malignancies usually arise in thymus, invade gills and 





Supplemental Figure 2.2. Malignancies show diverse patterns of dissemination. Diseased hlk fish demonstrating common patterns of invasion. 
GFP+ tumors typically have thymic origin (refer to Figure 1c and Supplemental Figure 1), and spread locally to gills (a) and other adjacent 
structures (b) (lower image in panel b shows higher magnification). Often, dissemination throughout the entire animal occurs (c). Skin is often 
heavily infiltrated (see histology in Figure 2), occasionally with discontinuous ‘skip lesions’ (lower fish in panel d). Tail (e) and peri-ocular tissues 






Supplemental Figure 2.3. Srk, hlk, and otg can also develop other malignancies. GFP- tumors 
are occasionally seen in srk, hlk, and otg animals. At top, fish with neoplasms of the left flank 
(srk), gill (hlk), and peri-anal (otg) regions are shown; tumors were grossly GFP- (not shown). 
H&E cross-sections at 2X (middle row) and 40X (bottom) display tumor involvement and non-
lymphocytic morphologies. In addition to their morphologic appearance, tumors were not grossly 
GFP+ (not shown) nor immuno-reactive with anti-GFP mAb (middle and bottom row inset 
images), suggesting they are not T cell malignancies. The srk tumor shows sarcoma-like 








Supplemental Figure 2.4. Tumors occasionally show a mature T cell phenotype. Twice-
sorted GFP+ cells from a second otg fish were analyzed by RT-PCR (compare to Figure 3). While 
lck, tcra, and cd4 again confirm T cell identity, here rag2 and cd8a are not present. This 
expression pattern is most consistent with tumor cells having mature T cell differentiation. Other 








Supplemental Figure 2.5. Malignant cells have lymphoblastic morphologies. Wright-stained 
cytospin preparations of WT marrow (upper left) and marrow from a diseased hlk fish (upper 
right). Dark blue infiltrating lymphoblasts are seen, having similar morphologies to those shown 
in Figure 4b. Unsorted cells from homogenized srk thymic tumor (bottom right) have identical 
appearance. Unsorted cell suspension from WT thymus (bottom left) is shown for comparison. 












Supplemental Figure 6. Malignancies are transplantable. FAC-sorted, GFP+ cells from srk, 
hlk, and otg tumors were IP-injected into irradiated WT hosts. Cell doses ranged from 2.5 x 103 to 
1 x 106 GFP+ cells, with higher doses showing higher rates of engraftment. By one week, GFP+ 
cells were seen at injection sites. Subsequently, tumors spread locally and then widely 













Supplemental Figure 7. Determination of leukemia-initiating cell number. The percentage of 
animals remaining disease-free from each transplant group (y-axis; note log scale) is plotted 
against injected donor cell number (x-axis). Each data point represents results from 5 recipients. 
Regression analysis was then used to generate straight lines fitting the dataset for each donor (fish 
A, circles; fish B, squares, fish C, triangles; R2-value = 0.977, 0.918, and 1.0, respectively). 
Leukemia-initiating cell frequency (LIC) is determined as the number of injected cells 
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 Zebrafish (Danio rerio) T cell acute lymphoblastic leukemia (T-ALL) models are useful 
tools for studying human cancer. Several transgenic and mutant D. rerio lines have been shown to 
develop T-ALL. One line with recessive T-ALL predisposition, oscar the grouch (otg), was 
identified in a mutagenesis screen designed to uncover aberrant T cell development. We have 
previously shown that otg-derived T cell cancers emulate human T-ALL. This suggests that otg 
cancers might be susceptible to human T-ALL therapies. Patients with ALL and zebrafish from 
the transgenic rag2::MYC-ER line affected with T-ALL respond with apoptosis and remission to 
treatment with glucocorticoids and γ-irradiation. Both treatments failed or had only limited 
efficacy in decreasing the disease burden in otg mutants. We tested if the otg mutation also 
confers resistance to irradiation-induced apoptosis in zebrafish embryos.  While DNA damage 
response is intact in otg mutant embryos, they exhibit diminished activation of caspase 3 and 
decreased apoptosis.  Genetic manipulation of otg mutant individuals revealed that the defect lies 
in the intrinsic mitochondrial-induced apoptosis pathway.  
 
Introduction 
Lymphocytic malignancies are the most common diseases in pediatric oncology.  
Relative to most other leukemias and lymphomas of childhood, those derived from the T cell 
lineage are also more difficult to cure and their treatments are often accompanied by acute side 
effects and long-term health risks (Larson et al 1998, Pui 1998, Takeuchi et al 2002). An 
additional challenge in understanding these diseases is that T cell malignancies are molecularly 
heterogeneous, driven by complex combinations of genetic changes (Ferrando et al 2002). 
Knowledge of specific molecular alterations that can cause T lymphocyte transformation has 
principally come from the discovery of aberrant chromosomal translocations and activation of 
pathways in blast cells from T-ALL patients (Armstrong and Look 2005, Pui et al 2004). While 




cases lack such cytogenetic changes (De Keersmaecker et al 2006, Harrison and Foroni 2002), 
making the causative events less transparent. Recent studies have identified NOTCH1 activation 
in over 50% of human T-ALL patient samples and cell lines (Weng et al 2004), and further 
studies have identified the c-MYC proto-oncogene as a direct target of NOTCH1 (Palomero et al 
2006). While these reports provide important insights into a subset of T-ALL, lesions in a large 
number of T-ALL cases have undoubtedly not yet been determined. Therefore, discovery of 
additionally pathogenic mechanisms is pivotal to both clinical medicine and scientific 
understanding to refine prognosis and treatment of T cell malignancies.  
 The idea that apoptosis might have a role in the treatment of malignancies was first 
suggested by Kerr et al who observed extensive nonnecrotic cell death after cancers were treated 
with cytotoxic agents (Kerr et al 1972, 1994). Consequently, defective apoptosis is one of the 
pillars of tumorigenesis (reviewed in (Lowe and Lin 2000)). For example, in lymphoproliferative 
cancers bcl-2 was identified as a promoter of cell survival by blocking programmed cell death 
(Hockenbery et al 1990, Lowe and Lin 2000, McDonnell et al 1989, Vaux et al 1988). In addition 
to over-expression of BCL2, inactivation of tumor suppressor genes such as p53 and Fas, and 
their effector genes (bax, apaf-1, casp9 and others) has been shown to cause apoptosis resistance 
in many different cancer types (Allan and Clarke 2009, Fadeel et al 2008, Mione and Trede 
2010). Defects in apoptosis can contribute to treatment failure (reviewed in (Andreasson et al 
2001) as the mechanism of action of many chemotherapeutic agents involves induction of 
apoptosis.  
 Zebrafish have recently become popular models for the study of human cancers, 
including hematological neoplasia (Amatruda and Zon 1999, Meeker and Trede 2008, Mione and 
Trede 2010)}. Five zebrafish models with T cell cancer predisposition have been described to 
date. Transgenic lines with lymphocyte-specific mis-expression of human NOTCH1 and murine 
MYC (mMYC) both develop T-ALL and T-LBL (Chen et al 2007, Langenau et al 2003). In a 




heritable germline mutations that also display highly penetrant T cell malignancy phenotypes 
(Frazer et al 2009). All of these ALL-prone lines have lymphocyte-specific GFP reporters, 
facilitating assessment of therapeutic interventions by fluorescence microscopy. Here, we used 
two of these T cell malignancy-prone lines, transgenic human rag2::MYC-ER (hMYC) and otg 
(Frazer et al 2009), to study response to common apoptosis-inducing T-ALL treatments. We 
report that one of these models, otg, has a defect in the intrinsic apoptosis pathway.  
Understanding the pathogenic mechanism of this zebrafish model stands to advance our 
understanding of the diverse molecular events that drive human T-ALL.  
 
Results  
Differential glucocorticoid sensitivity of zebrafish T-ALL models. The success of ALL 
treatment is based on the use of multimodal chemotherapy. Dexamethasone (DXM), a synthetic 
corticosteroid, plays an essential role in nearly all therapy combinations due to its ability to block 
cell cycle progression and induce apoptosis in ALL cells (Ploner et al 2005, Tissing et al 2003). 
DXM induces apoptosis by binding the glucocorticoid receptor (GCR), revealing its nuclear 
localization signal, and translocating with the GCR to the nucleus where the complex interacts 
with glucocorticoid response elements (GREs) leading to the transcriptional activation of 
proapoptotic genes (Tissing et al 2003).   Sensitivity to glucocorticoids is therefore a major 
prognostic factor in human T-ALL (Arico et al 1995, Dordelmann et al 1999). The hMYC (A. 
Gutierrez, pers. communic.) and otg zebrafish models of T-ALL (Frazer et al 2009) share many 
common features with human T-ALL. We therefore wished to determine whether these models 
were sensitive to treatment with DXM, similarly to their human counterparts. We established a 
treatment regimen where a maximum of 10% of leukemic hMYC individuals succumbed in the 
early treatment phase, possibly due to tumor lysis syndrome (see Materials and Methods). Of 17 
treated hMYC fish, 15 had responded by day 14, and 13 of 17 had achieved complete remission 




treatment protocol on 8 leukemic otg fish.  Six of these showed no response to DXM, one had a 
delayed response (28 days vs. 14 days) and one fish responded within the same timeframe as 
hMYC individuals (Figure 4.1, Table 4.1).  
Radiation therapy induces remission in zebrafish models of T-ALL. T-ALL is known for 
its exquisite sensitivity to irradiation, and radiation therapy has been used effectively in patients. 
Adult zebrafish respond to sublethal, single-dose γ-irradiation (20Gy) with T cell ablation within 
72 hours and resume hematopoiesis 21 days after treatment (Langenau et al 2004, Traver et al 
2004). To test the effectiveness of this treatment in our zebrafish models of T-ALL we conducted 
single-dose irradiation trials to induce remission as assessed by fluorescence microscopy 
(Langenau et al 2004, Traver et al 2004) (Figure 4.2a). Both hMYC, and otg fish remitted with a 
single dose of 20Gy. However, while this dose was sufficient to prevent relapse in all hMYC 
affected fish for at least 60 days, relapse occurred in otg fish as early as 10 days after treatment. 
Next we sought to determine the minimum single irradiation dose necessary to achieve a 
complete remission in hMYC leukemic fish.  To that end, we exposed affected hMYC fish to 
varying doses of γ-irradiation: 2 each at 17.5Gy, 15Gy, 12.5Gy, 10Gy, 7.5Gy, 5Gy. Exposure to 
10Gy or greater resulted in complete remission at 72 hours post-treatment for all 8 leukemic 
individuals, whereas exposure to 7.5Gy or 5Gy only induced remission in 25% (Figure 4.2b). We 
therefore chose single exposure to 10Gy to treat affected hMYC, and otg fish. As expected, 100% 
of hMYC fish remitted with this treatment regimen and remained in remission for at least 49 days 
after treatment (n=7). By contrast, only 83% of otg fish achieved remission at this dose (n=6), and 
60% of these had relapsed by 14 days after treatment (Figure 4.2c).  
 Otg embryos are resistant to irradiation-induced apoptosis. The marked decrease in 
radiation sensitivity of T-ALL in adult otg fish suggested a possible inherent resistance to 
irradiation-induced apoptosis in these animals. To test this, we used two different assays. First, 30 
hours post-fertilization (hpf) embryos were exposed to high dose γ-irradiation, and apoptosis was 




2010). Second, we exposed 18hpf embryos to 12.5Gy of γ-irradiation followed by acridine orange 
staining (Sidi et al 2008) to distinguish apoptosis from other forms of cell death. In otg 
heterozygote incrosses approximately one-quarter (429/1867, 23%) of the embryos exhibited no 
change in tail phenotype after treatment with 100Gy, indicating resistance to apoptosis, similar to 
p53 mutant embryos (Fig 4.3a). Similarly, approximately one-quarter (26%) of offspring from otg 
heterozygous crosses also excluded acridine orange following 12.5Gy of γ-irradiation, indicating 
resistance to apoptosis (Fig 4.3b).   
As γ-irradiation activates the intrinsic mitochondrial apoptotic pathway, we tested the 
integrity of the intrinsic mitochondrial pathway. otg embryos were exposed at 24hpf to 8Gy of γ-
irradiation, as described previously (Jette et al 2008) and apoptotic cells were revealed with an 
antibody to activated-human Caspase-3.  Using this assay, we observed that 45 out of 167 
embryos (26.9%) produced from the mating of a known otg heterozygous pair (Fig 4.3c) had only 
weak induction of  caspase 3, while three quarters of the embryos had wild type levels. In 
summary, all three assays confirm that irradiation-induced apoptosis, culminating in the 
activation of caspase 3, is impaired in otg mutant embryos.  
otg embryos have a defect in the intrinsic apoptosis pathway. Gamma-irradiation triggers 
the intrinsic apoptotic pathway in zebrafish  (reviewed in (Eimon and Ashkenazi 2010).  A well 
studied cascade of events, this pathway can be broken into three main phases: double-strand 
break repair regulated by the accumulation and localization of the γ-phosphorylated histone 
H2Ax (γ-H2Ax); the response of p53 and BCL-2 family members  (including Puma, Bax, Bad, 
and Bak) to permeabilize the outer mitochondrial membrane; and cytochrome c release followed 
by binding to APAF-1 and caspase-9 to form a holoenzyme that activates caspase-3 through 
proteolytic cleavage, resulting in cell-wide proteolysis and DNA cleavage (Eimon and Ashkenazi 
2010). 
To identify at which level the otg mutation exerts its effect, we investigated all three 




presence of γ-H2Ax has been shown to culminate at 30 minutes after irradiation and decrease 
thereafter (Sedelnikova et al 2002). As exaggerated repair activity can lead to apoptosis resistance 
in B-chronic lymphocytic leukemia (B-CLL) (Deriano et al 2005), particular attention was paid to 
the time-course of H2Ax phosphorylation. Using a polyclonal antibody directed against γ-
phosphorylated H2Ax, we examined 30hpf otg embryos at 10, 20, 30, and 40 minutes following 
100gy irradiation. Similarly to wild type controls, all otg embryos exhibited γ-H2Ax staining in 
cells of the neural tube beginning at 10 minutes post irradiation, with maximum signal at 30 
minutes post irradiation (Figure 4.4a). Similarly to control embryos, γ-H2Ax signal faded at 40 
minutes post irradiation in otg embryos, indicating an appropriate denouement of response to 
double-stranded breaks (data not shown).  
To ascertain if the mutation responsible for apoptotic resistance is distinct from p53, we 
performed complementation testing. Fish heterozygous for both p53 and otg do not develop 
leukemia nor are they resistant to apoptosis at the expected frequency. In addition, we utilized the 
Chk1 inhibitor Gö6976 to block the inhibitory pathway that prevents activation of caspase 2 after 
irradiation. This Chk1 inhibitor has been previously shown to restore apoptotic sensitivity to 
irradiation-induced apoptosis in p53 mutants (Sidi et al 2008).  While a nontoxic dose of Gö6976 
(1 µM) restored a complete apoptotic response to radiation in p53 mutants, no restoration of 
apoptosis, as detected by acridine orange, was achieved in otg embryos (Figure 4.4b, Figure 
4.4c), indicating that the mutation responsible for irradiation resistance in otg is not due to a 
mutation in p53.  
Irradiation activates puma transcription and protein expression in otg mutants. 
Following DNA damage by γ-irradiation, caspase-3 cleavage is dependent on p53 activation of 
the BH3-only gene puma but not other BH3-only proteins such as Bik, Bmf1, Bid or Noxa (Kratz 
et al 2006). This suggests that similarly to humans (Erlacher et al 2005) Puma is the primary 




expression of puma in otg embryos, we performed quantitative (q) RT-PCR analysis of puma 6 
hours after irradiation with 12.5Gy at 18hpf. In both wild type and otg embryos, γ-irradiation 
induced a greater than 12-fold increase in puma mRNA expression (Figure 4.5a). To address if 
puma mRNA in otg embryos is functionally deficient, we injected wild type and otg embryos 
with 10ng/µL of mRNA encoding puma at the one-cell stage of development, and followed their 
development during the first 2 hpf as described previously (Jette et al). Injection of puma had a 
profound effect on both wild type and otg embryos with very few surviving past gastrulation 
(Figure 4.5b). Injecting a range of doses of zpuma mRNA (1-10ng/µL) we observed no difference 
in the response of otg mutant and wild type embryos, suggesting that factors downstream of puma 
are intact, and their activation by exogenous puma injected at the one-cell stage is sufficient to 
induce apoptosis regardless of genotype.  
The ability of puma mRNA to induce apoptosis in otg embryos, coupled with the 
increased level of endogenous puma mRNA as measured by qRT-PCR in these embryos after γ-
irradiation (Figure 4.5a) may be explained by a mis-sense or non-sense mutation in the puma 
gene which leads to dysfunctional or degraded protein. Comparison of the coding sequence 
(including the 5’ and 3’ UTRs and the untranslated exons 1, 4 and 5) of puma cDNA derived 
from otg embryos and radiation-sensitive wild type embryos revealed no mutations that would 
result in an amino acid changes or a premature stop codon in these regions. Next, we tested 
whether in addition to expression of mRNA, Puma protein was detectable in otg fish.  To induce 
a vigorous response, we irradiated wild type, p53 mutant, and otg mixed clutches at 24hpf with 
100Gy, followed by Western blot experiments on protein lysates with a polyclonal anti-zebrafish 
Puma antibody. As expected, Puma protein levels were increased after high-dose irradiation in 
wild type embryos. otg embryos identified after irradiation by the straight/curled tail assay 
showed an increase in Puma protein after irradiation that was comparable to the increase seen in a 
pool of mixed homozygous wild type and heterozygous siblings (Figure 4.6). The neural tube is 




extremely difficult to study in isolation. We therefore examined Puma expression in isolated 
brains and spinal cords from irradiated adult homozygous otg fish and wild type controls. 
Western blotting for Puma protein in these samples showed no difference in Puma protein 
between wild type and otg samples (Figure 4.6), suggesting that irradiation resistance in otg 





 While the treatment of leukemias has improved greatly in recent years, success in curing 
T-ALL in particular is still challenging. Treatment of T-ALL is more aggressive, resulting in 
increased toxicity and potential long-term sequelae. More targeted therapies and a better 
understanding of the pathogenic mechanisms at work in T-ALL are required to improve treatment 
results and diminish side effects. To better understand the molecular mechanisms driving the 
pathogenesis of T-ALL, we studied a line of zebrafish, otg, that we previously identified in a 
mutagenesis screen as having a recessive hereditary predisposition to T-ALL (Frazer et al 2009). 
In the present study, we show that otg is resistant to treatment with treatments known to be 
effective in humans: dexamethasone and whole body irradiation. We find that this resistance to 
apoptosis ultimately results in a block of the intrinsic apoptosis pathway culminating in a loss of 
caspase 3 activation. Finally, we show that this mutation is not due to a loss of activity of tp53 or 
its direct downstream targets. However, over-expression of one such effector, puma, can rescue 
apoptosis in otg embryos. 
 The observation that the injection of puma mRNA into otg zebrafish results in a 
restoration of apoptosis, but that no mutation in the puma gene can be found, creates a paradox 
surrounding the mechanism behind the otg phenotype. Recently, new findings regarding 
phosphorylation as a post-translational modification of human PUMA (Fricker et al 2010) suggest 
that yet another level of regulation maintains the delicate balance of this key protein.  In that 




repressed cell death potential. This therefore suggests that the phosphatase responsible for 
dephosphorylating PUMA may be key player in promoting apoptosis if conserved across species, 
and a loss of function in this phosphatase in zebrafish might result in decreased apoptotic 
potential in the presence of puma activation as seen in otg embryos.  Our observations that over-
expression of zebrafish puma mRNA can restore apoptosis in otg embryos argues against a defect 
in this phosphatase. However, since  this phosphatase has not yet been identified, and its kinetics 
are therefore unknown, it is possible that the overexpression of puma mRNA may bypass the 
need for its proper function, resulting in apoptosis even in the face of a defective phosphatase.  
BAD, another proapoptotic member of the BCL2 protein family, promotes cell death by 
binding to and preventing the prosurvival functions of BCL-xL and BCL-2 (Yang et al 1995) 
BAD also acts to displace PUMA from BCL-2 or BCL-xL allowing BAX to move to the 
mitochondrial membrane, and directly activating cytochrome C ((Kim et al 2006). Additionally, 
previous studies have shown that the overexpression of bad in wild type zebrafish (by RNA 
injection) can promote increased radiation sensitivity (Jette et al 2008). However, gene 
overexpression of bad in otg mutants did not result in restoration of irradiation-induced apoptosis 
(data not shown). In zebrafish, Bad protein function is regulated by the phosphorylation status of 
serines 84 and 103. Phosphorylation prevents proapoptotic function and dephosphorylation 
allows Bad to initiate proapoptotic activity (Jette et al 2008) by dissociating from 14-3-3 in the 
cytosol, and moving to the mitochondrial membrane to inactivate Bcl-XL or Bcl-2 (Yang et al 
1995). A number of different phosphatases have been identified that dephosphorylate BAD in 
human cell lineages. These include PP1a in IL-2/IL-4 dependent T cell lines (Ayllon et al 2000), 
and PP2a in a prolymphocytic cell line (Chiang et al 2003). If dephosphorylation were inhibited 
in otg embryos due to a loss of function of the phosphatase responsible for this activity in 
zebrafish embryos, radiation-induced apoptosis would be expected to be impaired, as we observe 




understanding of the mechanism of irradiation-induced apoptosis, and a possible link between 
this pathway and the development of T cell malignancy. 
The lack of activated caspase 3 expression in otg embryos could be the result of a loss of 
function in any of the myriad components of the intrinsic apoptosis pathway which culminates in 
the caspase cascade. The post-mitochondrial signaling arm of this pathway is well studied in the 
zebrafish, and the players engaged after mitochondrial activation are well elucidated (Eimon and 
Ashkenazi 2010. We have sequenced cDNAs derived from acridine orange-negative otg embryos 
and did not observe any mutations in the coding regions of caspase 3a, caspase 9, xaip , zaif or 
Apaf-1.  This does not completely rule out a primary defect in post-mitochondrial signaling, and a 
mutation in other genes responsible for activating the cascade (e.g. birc family members) could 
explain the irradiation resistance seen in otg. A second pathway known to activate caspase 3 in 
response to irradiation is sphyngo,myelinase induction of ceramide production, a second 
messenger that initiates caspase 3-mediated apoptosis. Defects in generating ceramide have been 
shown to lead to apoptosis following γ-irradiation  {Kolesnick, 2003 #96, Kolesnick and Fuks 
2003) and to leukemia (Kim et al 2008).  We have not found a mutation in the neutral 
sphyingomyelinase 2 or acid sphyngomyelinase 3/4 genes of otg mutants, but defects in any of 
the other factors in this pathway may be responsible for the loss of irradiation sensitivity seen in 
otg. 
Since the mutated gene responsible for the otg phenotype has not yet been identified, the 
genetic explanation for the dual phenotype of otg (leukemic predisposition and apoptosis 
resistance) remains an exciting mystery. Although otg was originally identified based on a 
leukemic predisposition phenotype in the adult, subsequent studies revealed an embryonic 
irradiation resistance phenotype that bolsters the impact of this mutation. Gaining a more 
comprehensive understanding of apoptosis-induction and the loss of apoptotic potential are 
becoming critical to the fields of cancer pathogenesis and treatment. For these reasons, otg is 




Materials and methods 
Zebrafish transgenic lines. The otg line of zebrafish was identified in a mutagenesis 
screen performed on lck::EGFP zebrafish on the WIK background as described previously (Frazer 
et al 2009). rag2::hMYC-ER zebrafish were a gift from Alejandro Gutierrez (DFCI, Boston, MA).  
Imaging of adult leukemic zebrafish. Fluorescent imaging of adult leukemic zebrafish 
was done on an Olympus MVX10 microscope (Center Valley, PA). Images were taken using a 
Spot Insight 14.2 color mosaic camera (Diagnostic Imaging, Sterling Heights, MI) and Spot 4.6 
software with the following color capture settings: Red:1; Green:2.5; Blue: 2.8 
Dexamethasone treatment of adult leukemic zebrafish. Dexamethasone (DXM) was 
delivered by adding the drug directly to the fish water. Adult fish were kept in 1L bottles in 
500mL of fish water (pH 7.2, conductivity of 500 µs,). Water was changed daily for 2 weeks with 
replacement of drug with each water change during the first 2 weeks, and fish were then placed 
back in water without drug after the treatment period. A high death rate (>75 %) was observed at 
initial DXM doses beyond 4µg/mL (10µM) (see Supplemental Table 1). As nonleukemic fish 
treated with the same dose survived without incident, we attributed the high death rate of 
leukemic fish to tumor lysis. We therefore established the following protocol using incremental 
increases of DXM dose: 0.5 µg/mL DXM for 7 days, then 2.0 µg/mL for 3 days, then 4.0 µg/mL 
for 4 days. Complete remission was defined as a total loss of recordable GFP signal as 
determined by our imaging settings (see above). A response to dexamethosone was defined as a 
decrease in GFP signal easily discernible by eye.  
Radiation treatment of adult leukemic zebrafish. Adult zebrafish were placed, in 
ultracentrifuge bottles containing 250mL of fish water, in a 137Cs source irradiator (Mark I-30 
Irradiator, J.L. Shepherd and Associates, CA) and exposed to 6.25 Gy/minute. To achieve an 





Radiation treatment of zebrafish embryos. For high-dose irradiation (IR), embryos were 
placed in a 137Cs source irradiator (Mark I-30 Irradiator, J.L. Shepherd and Associates, CA) and 
exposed to 25 Gy/minute for a total of 100Gy. For low-dose irradiation, embryos were exposed to 
6.25 Gy/minute.  Apoptosis was assayed at 6 hours following IR treatment by soaking embryos in 
50 µg/mL of Acridine Orange (Sigma, St. Louis, Missouri) for 45 minutes and subsequent de-
staining by washing in embryo water 5x 5mins.  
Whole-mount zebrafish caspase-3 assay. After irradiation, embryos were fixed and 
prepared for staining as described previously (Jette et al 2008) with minor modifications. Anti-
activated human Caspase-3 primary antibody was used at 1:500 dilutions (BD Biosciences, San 
Jose, CA) and goat anti-rabbit IgG Alexa Fluor 488 (Invitrogen, Carlsbad, CA) was used as a 
secondary antibody at 1:200. 
Whole-mount zebrafish γ-H2Ax immunofluorescenc. γ-phosphorylated zebrafish histone 
H2Ax (γ-H2Ax) was detected using a polyclonal anti-γ-H2Ax antibody (1:500) that was 
generously provided by James Amatruda (University of Texas Southwestern, Dallas, TX), and an 
Alexa 488-conjugated secondary goat anti-rabbit antibody (1:1,000; Invitrogen, Carlsbad, CA). 
Staining was done according to Rhodes et al 2009 with minor modifications. 
             Embryo treatment with Chk1 inhibitor, Gö6976. Immediately before IR, 18-hpf embryos 
were dechorionated and transferred to fresh egg water containing 1% DMSO, with or without 
Gö6976 (1µM; Calbiochem, Gibbstown, NJ). Embryos were exposed to the inhibitor for 6 hrs, 
transferred to fresh egg water, rinsed in embryo water five times each for 5 min, and labeled with 
AO as described above. 
Quantitative RT-PC. Analyses were performed using the Roche Lightcycler 480 II qRT-
PCR system according to manufacturers instructions. All experiments were performed in 
triplicate, and normalized against the constitutively expressed zebrafish gene ef1α. Primers for 









Microinjections. Zebrafish one-cell stage embryos were injected with 10ng/µL 
(approximately 30pg/embryo), 3ng/µL (approximately 10pg/embryo), or 1ng/µL (approximately 
3pg/embryo). To control for variation in the survival of embryos after the mechanical stress of 
injection, 0ng/µL mRNA (injection of dye only) control was included with each set of embryos 
injected. Surviving embryos were counted at 2h, 4h, and 24h after injection. 
Sequencing of puma coding regions.  RNA from pooled acridine orange-positive and -
negative embryos was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA) and cDNA was 
created using iscript  cDNA from Bio-Rad (Hercules, CA). cDNA from otg and wild type 
embryos was amplified using the following primer sets and sent for immediate sequencing after 
nucleotide cleanup using QIAGEN  PCR purification kit (Valencia, CA) at MC Labs, South San 
Francisco, CA: 
Puma 5’UTR and untrans ex 1_F: 5’ tgaaaggactttgctgtcatc 3’ 
Puma 5’UTR and untrans ex _R: 5’ gtggtgcagagagagtgctg 3’ 
Puma Translated F: 5’ tgtatgtggagcaggctaactg 3’ 
Puma Translated R: 5’ cctgcagaaaaatcccagag 3’ 
Puma untrans exon 4_F: 5’ acgctgtcttccttcagagg 3’ 
Puma untrans exon 4_R: 5’ attgccaggtttttgtaccg 3’ 
Puma untrans exon 5A_F: 5’ gggatcttgatctttcctcca 3’ 
Puma untrans exon 5A_R: 5’ cgggggatttacatgatgac 3’ 
Puma untrans exon 5B_F: 5’ tgcttcacatgcaagaatca 3’ 
Puma untrans exon 5B_R: 5’ cgctcaataaattagcttgtgct 3’ 
Puma untrans exon 5C, 3’UTR_F: 5’ acccctctccccatgataaa 3’ 
Puma untrans exon 5C, 3’UTR_R: 5’ tcaactgactaacaataacaacacaaa 3’ 
 
Western blotting: Pooled embryos were dechorionated, then collected into phosphate buffered 
saline (1xPBS), and repeatedly cooled on ice for 5 minutes, agitated , and washed with 1xPBS 3 
times  to remove attached. De-yolked embryos were lysed using RIPA buffer containing 
benzonase (Novagen, Gibbstown, NJ) and protease inhibitors cocktail (Sigma, St. Louis, MO) 




lane of a 15% SDS-PAGE gel. The gel was run at 120V for 70 minutes in 1x SDS buffer and 
transferred to a PVDF membrane for 2 hours at 100V at room temperature in a Bio-Rad transfer 
apparatus. Rabbit polyclonal anti-zebrafish Puma (a gift from Cicely Jette, Univ. of Utah) was 
used at 1:250 dilution, and a donkey anti-rabbit HRP-conjugated secondary antibody (Bio-Rad) 
was used at 1:10,000 dilution. Anti-histone H3 antibody (Abcam, Cambridge, MA) was used as a 
loading control at 1:2000.  
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Figure 4.1.  otg leukemic fish respond poorly to dexamethasone treatment. Leukemic hMYC  (n=17) and otg fish (n=8) were treated with 
dexamethasone for 14 days. Dosing was incremental: 0.5 µg/mL DXM for 7 days, 2.0 µg/mL for 3 days, and 4.0 µg/mL for 4 days. 15/17 hMYC 




Figure 4.2. Single dose radiation treatment of hMYC and otg leukemic fish. (a) 
Representative fluorescent images of hMYC and otg leukemi fish treated with a single dose of 
20Gy of γ-irradiation . While both fish achieve complete remission from this single dose, the otg 
fish relapsed by 10 days post treatment and the hMYC fish did not relapse until 60 days after 
irradiation. (b) hMYC fish were treated with a number of different doses to determine the 
smallest single dose able to induce remission in all fish. This dose was determined to be 10Gy. (c)  
Leukemic hMYC (n=7) and otg (n=6) were treated with a single 10Gy dose of γ-radiation.  A 
graph of relapse percentages shows that all of the hMYC fish achieved remission with this dose, 
while only 83% of the otg fish achieved complete remission. Additionally, nearly all hMYC  fish 
either remained in complete remission throughout the 60-day study (5/7) with 2 fish relapsing at 
49 and 60 days after treatment. Of the 5 otg fish who attained remission, 2 relapsed as early as 12 







Figure 4.3.  Demonstration of resistance to irradiation-induced in otg zebrafish embryos. Embryos at 30hpf (a) or 18hpf (b,c) wild type, p53-/- 
and mixed otg heterozygous embryos were exposed to 100Gy (a) or 12.5Gy (b,c) of γ−irradiation. After 6 hours, embryos in (a) were sorted based 
on tail curl phenotype. In (b), following irradiation, embryos were treated with acridine orange at 50ug/mL and sorted based on acridine orange 
staining in the head and tails. In clutches from otg+/- parents, 74% of offspring had high levels of acridine orange staining, and 26% had low levels. 
In (c) embryos 6 hp irradiation were fixed and stained with a polyclonal anti-human activated caspase 3 antibody. After staining, embryos from 




Figure 4.4.  Double strand break repair and Chk1 signaling are normal in otg mutant 
zebrafish embryos. (a) 30hpf otg embryos were irradiated with 100Gy then fixed at 10, 20, 30, 
or 40 minutes after irradiation and stained with a polyclonal anti-γH2Ax antibody. Recruitment of 
γH2Ax increased after irradiation and reached a maximum at 30 minutes post exposure. No 
difference was detected between otg embryos and wild type embryos. (b) p53-/- and otg embryos 
were irradiated at 18hpf with 12.5Gy then treated with the chk1 inhibitor Gö6976 for 6 hours and 
s.2tained with acridine orange. (c) While p53-/- embryos were re-sensitized to irradiation-induced 

































































Figure 4.5. puma mRNA expression and induction of apoptosis are normal in otg embryos. (a) 18hpf wild type and otg embryos were 
irradiated with 12.5Gy, and 6 hours after irradiation puma mRNA expression was analyzed by qRT-PCR. Irradiation induced the expression of 
puma mRNA in both, wild type and otg embryos, at greater than 12 times baseline levels. (b) When puma mRNA was injected into single cell otg 
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Figure 4.6. PUMA protein expression is normal in otg adults and embryos after irradiation. Wild type and otg adults and 24hpf embryos 
were irradiated with 100Gy and protein lysates were prepared 8 hours after irradiation. Puma protein was detected by probing with a rabbit anti-
zebrafish polyclonal antibody. Adult brains and whole embryos of both wild type and otg fish showed expression of Puma protein, regardless of 
genotype. Zebrafish Puma protein is approximately 24kD, and histone H3 was used as a loading control (20kD).  
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Table 4.1. Dexamethasone treatment of hMYC and otg leukemic fish 
     
     
     
Fish strain d14 response d21 response d28 response 
       
5-10 hMYC CR CR VGPR 
5-11 hMYC VGPR VGPR CR 
5-12 hMYC VGPR VGPR VGPR 
5-13 hMYC CR CR VGPR 
5-14 hMYC VGPR VGPR VGPR 
5-15 hMYC GPR GPR GPR 
6-15 hMYC GPR GPR GPR 
6-16 hMYC VGPR VGPR VGPR 
7-1 hMYC died d1 n/a n/a 
7-2 hMYC VGPR VGPR CR 
7-3 hMYC PR Rel Rel 
8-1 hMYC died d9 n/a n/a 
8-2 hMYC CR n/a n/a 
8-3 hMYC CR CR n/a 
9-1 hMYC VGPR PR PR 
9-2 hMYC CR CR CR 
9-3 hMYC VGPR n/a n/a 
       
7-1 otg NR n/a n/a 
7-2 otg NR NR NR 
7-3 otg NR NR n/a 
7-4 otg PR NR NR 
8-1 otg NR NR NR 
8-2 otg NR NR NR 
9-1 otg CR PR PR 
9-2 otg NR NR NR 
NR = no response; PR = partial response; GPR = good partial response; VGPR 
= very good partial response; CR = complete remission; n/a = not applicable due to 




Supplemental Table 1. Titration of Dexamethasone Exposure in 
hMYC Zebrafish  
    
No. of Fish Exposure  (µg/ml) Death Rate (%) Response Rate 
      By d21  
4 250 4 (100%)   
4 100 4 (100%)   
4 10 3 (75%) 3 
4 2 1 (25%) 4 
4 1 0 4 
9 1(7d) + 4(7d) 2 (22%) 9 
6 1(7d) + 2(3d) + 4(4d) 3 (50%) 6 
6 1qOD(7d) + 2(3d) + 4(4d) 3 (50%) 6 
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T cell acute lymphoblastic leukemia (T-ALL) is a challenging entity with high rates of 
induction failure and relapse. To discover genetic changes occurring in T-ALL, and those 
contributing to relapse, we studied zebrafish (Danio rerio) T-ALL samples using array 
comparative genomic hybridization (aCGH). We performed aCGH on 17 T-ALLs, representing 4 
zebrafish T-ALL models, and evaluated similarities between humans and zebrafish by comparing 
all D. rerio genes with copy number aberrations (CNAs) to a cohort of 75 published human T-
ALLs analyzed by aCGH. Within these D. rerio CNAs, we identified 893 genes with human 
homologues and found significant overlap (63%) with the human dataset. In addition, when we 
restricted our analysis to primary T-ALLs (14 zebrafish and 61 human samples), 10 genes were 
recurrently altered in >3 zebrafish samples and >4 human T-ALL cases, suggesting a conserved 
role for these loci in T-ALL transformation across species. We also conducted iterative allo-
transplantations with 3 zebrafish malignancies. This technique selects for particularly aggressive 
disease, results in shorter survival times in successive transplant rounds, and models refractory 
and relapsed human T-ALL. Fifty-five percent of original CNAs were preserved after serial 
transplantation, demonstrating shared clonality between each primary and passaged leukemia. 
Additionally, T-ALLs acquired an average of 34 CNAs during passaging. Genes in these loci may 
underlie the enhanced malignant behavior of these neoplasias. We also compared genes found in 
CNAs of passaged zebrafish malignancies to human aCGH results from 50 T-ALL patients who 
failed induction, eventually relapsed, or already had relapsed. Again, many genes (88/164) 
overlapped in both datasets. Additionally, 9 genes altered in 2 of 3 passaged D. rerio samples 
were also found in several human T-ALL cases. These results suggest that zebrafish and human 
T-ALLs are similar at the genomic level, and are governed by factors that have persisted 






 Genomic alterations are a prominent feature of cancer, and include aneuploidy, 
chromosomal translocations, and focal amplifications and deletions. Some changes foster 
oncogenic transformation, while others favor the outgrowth of specific sub-clones in an already 
established neoplasia (Mullighan et al 2008). Gain or loss of certain genes can promote tumor 
development, metastasis, drug resistance, or other clinically pertinent features. Finally, specific 
genomic changes associated with a particular malignancy type may correlate with prognosis 
(Armstrong and Look 2005). Consequently, the identification of recurrent genomic anomalies 
contributes to our understanding of cancer.  
 To detect acquired CNAs, aCGH has been widely applied to human cancers (Pinkel and 
Albertson 2005) and is likewise amenable to model organisms (Hodgson et al 2001, Maydan et al 
2007, Thomas et al 2007). Recently, zebrafish (Danio rerio) aCGH genomic platforms have 
become available. An initial D. rerio array contained 286 BAC clones enriched for homologous 
human oncogene and tumor suppressor sequences, with an approximate 5 Mb resolution 
(Freeman et al 2009). Newer high-density oligonucleotide arrays based on more accurate 
genomic assemblies (Peterson and Freeman 2009), have even greater resolution. 
 As vertebrates, zebrafish share most human genes and these genes usually have 
conserved actions. Specifically, many D. rerio homologues of human oncogenes and tumor 
suppressors also have the same function, making this organism an excellent model to study 
human cancers (Mione and Trede 2010). Supporting this, several transgenic zebrafish lines that 
mis-express mammalian oncogenes develop near-identical malignancies to humans (Chen et al 
2007, Langenau et al 2003, Langenau et al 2007, Patton et al 2005, Sabaawy et al 2006). 
Moreover, in studies of zebrafish cancers, CNAs with putative D. rerio oncogenes and tumor 
suppressors are readily detected (Freeman et al 2009). 
 For zebrafish to be an optimal model to study human cancer, the genes in D. rerio CNAs 
must be pertinent to human disease. CNAs containing homologous genes from the same tumor 
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type across both species may identify unappreciated players in human neoplasia. To test this 
hypothesis, we performed aCGH on 17 zebrafish T-ALL samples and compared results to aCGH 
findings in human T-ALL (Gutierrez et al 2010a, Mullighan et al 2007, Mullighan et al 2008). 
We concentrated on recurrently-altered genes in both human and zebrafish cancers, and those 
genes shared by leukemias with particularly malignant clinical behavior. Collectively, these 
analyses show a striking overlap between T-ALL CNA genes across species, and support 
zebrafish as a model pertinent to human leukemogenesis and disease progression.  
 
Results and discussion 
 We used aCGH to detect somatically-acquired CNAs in 17 zebrafish T-ALLs. These 
represent cancers from 4 D. rerio genetic models: 1 transgenic line mis-expressing murine c-Myc 
(mMyc) (Langenau et al 2005) and 3 mutant lines with heritable T-ALL predisposition (hlk, srk, 
otg) (Frazer et al 2009). Genomic DNA of non-malignant tissue from each cancer-bearing fish 
was used as a hybridization control to eliminate detection of inherited germline copy number 
variants (CNVs). T cell receptor (TCR) loci on chromosomes 2 and 17 served as internal controls 
(Supp. Figure 1), as deletions normally occur in these regions during T cell receptor 
recombination. (Haire et al 2000, Meeker et al 2010, Schorpp et al 2006). TCR deletions and 
other CNAs from wild-type D. rerio T cells (pooled from 25 zebrafish) were eliminated from 
consideration in subsequent analyses, as they are unlikely oncogenic (processing algorithm 
detailed in Supplemental Materials and Methods).  
 Using two zebrafish aCGH platforms, a total of 840 cancer-specific CNAs were detected 
comprised of 335 amplifications and 505 deletions, averaging 49.4 total CNAs per sample (Supp. 
Table 5.1, Supp. Figure 5.2a in Supp. Files). Eight T-ALLs were hybridized to a NimbleGen 
oligonucleotide array; a higher-density Agilent array was used for 9 other D. rerio samples. 
Amplifications and deletions averaged 197 and 135 kb, respectively. Depictions of all 17 
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zebrafish T-ALL genomes and pooled normal T cells are shown in Supplemental Figures 5.1 and 
5.3 (please see Supp. Files).  
We investigated 3 D. rerio cancers by aCGH using a unique approach only possible in an 
animal model. We iteratively passaged these T-ALLs (one leukemia from each of the srk, hlk, and 
otg lines) by serial allo-transplantation [(Frazer et al 2009, Rudner et al 2010) and Figure 1a]. Our 
prior studies have shown that iterative transplantation of small numbers of cells (1x105) selects 
for aggressive disease, with recipient survival times declining in subsequent rounds. We 
hypothesize that in vivo passaging favors aggressive sub-clones comprising a minor fraction of 
the original malignancy. It may also select for new mutations that promote more aggressive 
disease features. In another zebrafish T-ALL model, individual cells have been shown to act as 
leukemic stem cells to transmit disease (Smith et al 2010). This approach would eliminate clonal 
selection and optimize isolation of new mutations. However, because clonal evolution and new 
mutations are both integral to relapse in human patients (Choi et al 2007, Mullighan et al 2008, 
Panzer-Grumayer et al 2005), we opted to impose a 100,000 cell bottleneck. We believe that 
using a small number of donor cells allows both processes to occur, mimicking the clinical 
scenario of human T-ALL relapse where rare clones repopulate the leukemic pool as suggested 
previously (Ren et al 2009).  
We compared these 3 “passaged” T-ALLs to their “primary” counterparts. In these 6 
cancers, new CNAs were observed that could be linked to aggressive clinical behavior (Figure 
5.1b and Supp. Figure 5.3 in Supp. Files). Overall, serially-transplanted T-ALLs had a 
comparable number of CNAs (62.0 vs. 51.3; Supp. Table 5.2). Many CNAs of de novo T-ALLs 
(55%) were preserved in their passaged counterpart, demonstrating the clonal relationship 
between paired leukemias. Serially-transplanted cancers lost 45% of CNAs present in the 
primary, which may indicate that these were “passenger” events that did not contribute to 
oncogenesis. In addition, this phenomenon suggests the outgrowth of a dominant clone (or 
clones) lacking some CNAs present in the original. Passaged clones display more aggressive in 
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vivo behavior [(Frazer et al 2009, Rudner et al 2010) and Figure 1a], and genetic changes in 
derivative cancers may identify loci responsible for this phenotypic drift. In this study, we 
detected 101 new CNAs (54% of CNAs in serially-transplanted T-ALLs), that are putatively 
linked to increased aggressiveness.  
To explore similarities in genomic instability between D. rerio and human T-ALL, we 
examined aCGH results from 75 human T-ALL samples obtained from 61 patients. These 
patients were from 3 cohorts: Children’s Oncology Group Study P9404, n=40; Dana Farber 
Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocol 00-01, n=7; St. Jude 
Cancer Research Hospital (SJCRH) patients treated from 1995-2003, n=14 (Gutierrez et al 2010a, 
Mullighan et al 2007). The SJCRH cohort also contributed aCGH results from the same 14 
patients using DNA acquired at relapse. In total, these 75 T-ALL samples had 1578 CNAs (mean 
24.2/genome), with 510 amplifications and 1068 deletions (Supp. Figure 5.2b in Supp. Files and 
Supp. Table 5.1). The prevalence of CNAs and relative frequency of deletions vs. amplifications 
were quite similar in human and zebrafish T-ALLs (Supp. Table 5.1). Zebrafish CNAs were 
smaller and more abundant than those in human T-ALLs, but these differences likely derive from 
disparate genome sizes, inaccuracy of the D. rerio genomic assembly, and varying probe densities 
in the different hybridization platforms used.   
To compare the two datasets, we focused on “CNA genes” common to human and 
zebrafish T-ALL. To identify homologous genes shared by both species’ CNAs, we first 
identified every known D. rerio gene located within all 840 CNAs of our 17 zebrafish 
malignancies. From this list, we removed genes located in aneuploid chromosomes or other 
lesions >3 Mb, and from CNAs seen in normal T cells. Overall, 29% (5/17) of D. rerio T-ALLs 
had at least one trisomy, and others had large amplifications or deletions that we also excluded 
(details in Supp. methods). This degree of genomic instability was similar to human T-ALLs, 
where 25% (19/75) were aneuploid. This paring resulted in a list of 943 genes from CNAs of one 
or more D. rerio T-ALL (Supp. Table 5.3). We then manually ascertained whether human 
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homologues existed for these 943 genes using online databases and search tools (Supp. methods). 
Over 98% (n=926) of these genes had human counterparts, permitting a thorough cross-species 
comparison and emphasizing the high conservation between these two vertebrates.  
We compared this list to CNA genes of the 75 human T-ALLs described above. Of the 
926 zebrafish CNA genes, 33 were seen in human germline CNVs and removed from analysis 
(see Supp. Methods), leaving 893 homologous gene pairs. Of these 893 D. rerio genes, 558 
(62.5%) were also amplified or deleted in at least 1 human T-ALL (Table 5.1). Because human 
studies used single nucleotide polymorphism microarrays, loss of heterozygosity (LOH) was also 
detected in human T-ALL cohorts. If copy-neutral LOH events were also considered, even 
greater overlap was seen between the D. rerio and human datasets (597/893; 66.9%).  
Because many human genes occurred in at least one T-ALL CNA, the significance of this 
concordance is diminished. Therefore, we focused only on genes recurrently altered in both D. 
rerio and human T-ALL. We compared CNA genes present in more than 1 zebrafish T-ALL to 
human homologues present in multiple cases (Table 5.1). Of the 558 CNA genes in T-ALLs of 
both species, 253 were seen in 2 or more D. rerio samples, and of these, 94 (37.2%) also occurred 
in at least 2 human T-ALLs. Applying these same criteria more stringently, 65 CNA genes were 
found in >3 zebrafish cancers, with 26/65 (40%) occurring in at least 2 human T-ALLs and 15/65 
(23.1%) seen in >5 human cases. The intersection of these two datasets holds great potential to 
discover key genes fundamental to T cell malignancy.  
In the prior analysis, we identified recurring CNA genes from primary, passaged, and 
relapsed T-ALLs of both species. We next refined this dataset by restricting our comparison to 
only primary T-ALLs. Of the 75 human samples, 61 were primary T-ALLs. We compared CNA 
genes from these cases to those in our 14 zebrafish primaries. From our initial set of 926 zebrafish 
CNA genes, 768 genes derived from primary cancers. Of these, 472 (61.5%) occurred in at least 
one human primary T-ALL CNA (Table 5.1). We next concentrated on recurrent CNA genes 
from D. rerio and human T-ALL. Nearly half of these 472 shared CNA genes (218; 46.2%) were 
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seen in multiple human cases (Table 5.1). To distinguish the most promising candidates, we 
identified CNA genes seen in multiple human and D. rerio primaries. Ten genes occurred in >3 
zebrafish and >4 human T-ALLs (Supp. Table 5.4). This short list may represent unrecognized 
oncogenic factors in T-ALL, as their repeated occurrence in CNAs of these divergent species is 
unlikely to be coincidental. CNAs of these 10 genes were not only recurrent, but also focal, 
further suggesting that these genes may be oncogenic drivers. High resolution depictions of all 
zebrafish CNAs seen involving 4 of these genes are shown in Figure 5.2 (please see Supp. Files).  
One of these genes, TGFBR1 (seen in 5 D. rerio and 7 human samples), has already been 
implicated in T-ALL by aCGH (Remke et al 2009). Other genes with established roles in T-ALL 
[NOTCH1, PHF6, HES1; (Van Vlierberghe et al 2010, Weng et al 2004, Weng et al 2006)] 
occurred as focal CNAs in single zebrafish samples. Additionally, CNAs containing the T-ALL 
oncogenes LYL1, TAL1, TAL2, HES6, MLL4, and JAK2 were also seen, but were excluded from 
our analysis since they derived from large chromosomal gains. However, despite these 
similarities in T-ALL biology, the other 9 recurring genes in both species (Supp. Table 5.4) are 
not yet recognized as important factors in T-ALL, although they are frequently rearranged in 
human cases (Gutierrez et al 2010a, Gutierrez et al 2010b, Mullighan et al 2007, Remke et al 
2009).  
Curiously, several genes with known oncogenic properties in human T-ALL, such as 
CDKN2A, CDKN2B, PTEN, LEF1, WT1, and MYB/AHI1, were not seen in zebrafish. CDKN2A, 
the gene most often deleted in human T-ALL (Sulong et al 2009), is not present in D. rerio, so its 
absence from our analysis was expected; the absence of CDKN2B deletions may suggest 
differences between the two species. Additionally, genomic rearrangements are only one means 
to disrupt normal gene function, and loci absent from CNAs may still be perturbed by other 
mechanisms. The absence of CNAs involving MYB/AHI1, LEF1, PTEN, and WT1 from 17 D. 
rerio T-ALLs is not statistically compelling, as CNAs of these genes are infrequent in human 
cases (<12%). Moreover, both PTEN and WT1 are duplicated in trans in the zebrafish genome. 
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This redundancy may obviate their roles as lynchpins in D. rerio T-ALL, as deletion of all 4 
copies of either tumor suppressor is unlikely. Notably, CNAs of PTEN-induced putative kinase 1 
(pink1) occurred repeatedly in D. rerio (3/17; 17.6%), possibly representing an alternative 
mechanism to disrupt Pten function. Finally, 2 other CNA genes in D. rerio T-ALL, prkca and 
tfdp1, were not found in the 75 human cases used for comparison, but CNAs of their homologues 
have been reported in other human T-ALLs (Remke et al 2009).  
As a final comparison, we identified CNA genes from serially-passaged zebrafish T-
ALLs and analyzed them with respect to relapsed human cases. Amplified and deleted genes of 
passaged, but not primary, T-ALLs may explain transformed cells’ acquisition of new aggressive 
features. Our transplantation model creates highly malignant T-ALLs, and uses in vivo selection, 
which preserves biologic constraints absent in cell culture. In this respect, our experimental 
system mimics aspects of clinical relapse [(Frazer et al 2009, Rudner et al 2010), and Figure 
5.1a].  
We passaged 3 T-ALLs (1 hlk, 1 srk, and 1 otg) until each cancer rapidly engrafted and 
killed all recipients (in the 3 series, recipient death occurred 14.7 days earlier, on average, in the 
final round: 13.2 vs. 27.9 days). Final-passage and primary leukemic samples were then analyzed 
by aCGH to detect newly-acquired CNAs (Figure 5.1b and Supp. Figure 5.3 in Supp. Files) that 
contained a total of 164 D. rerio genes with human homologues. Remarkably, 9 of the 164 genes 
were altered in 2 passaged T-ALLs (Supp. Table 5.4), a significant finding as these leukemias 
derived from different mutant lines. Furthermore, 8 of these 9 genes were not seen in any D. rerio 
primary T-ALL, suggesting they may not be required for oncogenesis. Rather, these genes are 
predicted to contribute to malignant progression by our assay.  
We also compared these 164 genes to the human dataset. Because passaged cancers 
represent the most aggressive zebrafish T-ALLs, we focused on human cases with the worst 
outcomes – induction failures and relapses. Cancers in these human cases persisted despite multi-
agent treatment, and their CNA genes may be candidates contributing to therapeutic failure. 
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Specifically, we evaluated CNA genes from samples of patients who achieved remission but later 
relapsed (n=27), relapsed samples themselves (n=14), and 9 patients who failed induction (Table 
2). In aggregate, these 50 samples had CNAs of 88/164 (53.7%) genes from our passaged T-
ALLs. All of the 9 recurring genes from passaged zebrafish T-ALLs were also present as human 
CNA genes. In fact, all 9 genes were still coincident when we limited analysis to only the 23 
worst cases (14 relapses and 9 induction failures). Moreover, 8 of the 9 genes occurred in 
multiple cases of poor outcome human T-ALL, with 6/9 seen in >5 cases (Supp. Table 5.4). 
Remarkably, CNAs of these genes were common in relapsed and induction failure cases, but 
rarely occurred in 25 cases that achieved event free survival (Supp. Table 5.4). Thus, CNAs of 
these loci correlate strongly with T-ALL treatment failure.  
These 9 genes, encountered repeatedly in CNAs from aggressive disease in both species, 
may be prognostic factors in human T-ALL. Additionally, CNAs of these loci may not only 
predict therapeutic failure, but also identify pathways governing poor outcome at the molecular 
level. Together with the 10 recurring CNA genes shared by primary zebrafish and human T-
ALLs, our cross-species comparisons have identified a short list of genes of potential importance 
to T cell malignancy. Further testing is needed to interrogate this premise, but our data clearly 
suggest that critical genetic similarities exist between these species’ cancers, and that 
fundamental properties governing oncogenesis and disease progression have persisted over eons 
of evolution.  
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Figure 5.1. Serial transplantation shows clonal evolution of aggressive disease. T-ALL 
cells from 1 donor otg fish were sequentially passaged through 5 iterations of irradiated hosts. 
1 x105 cells were transplanted into each recipient. (a) Kaplan-Meier survival curves for 
engrafted fish are plotted [1st host cohort, n=11 (red); 2nd cohort, n=8 (blue); 5th cohort, n=10 
(green); rounds 3 and 4 are not shown for clarity]. One fish from each cohort (not plotted) was 
sacrificed to be the donor for the next transplant series. Recipients had statistically significant 
differences in mean survival duration for each transplant round (p values listed in figure). (b) 
Partial genomic representations (Chromosomes 18-25) of the otg primary T-ALL donor and a 
5th passage T-ALL. aCGH results are normalized to non-malignant tissue DNA of the original 
donor. Red lines depict deletions, green lines reflect amplifications, and line lengths 
correspond to heterozygous vs. homozygous deletions. Most CNAs are common to both 
samples, demonstrating clonality. CNAs gained or lost in 5th passage may reflect selection of a 
sub-clone that was a minor population of the original T-ALL and/or new CNA events. Some 
new CNAs may underlie the more malignant phenotype of the 5th passage. Copy number 







Table 5.1. Shared CNA Genes in Zebrafish and Human T­ALL             
             
Shared CNA Genes in 17 D. rerio and 75 Human T­ALLs             













T­ALLs # of genes with human homologues  893  640  253  65  26  6 # in human T‐ALL, gain or loss only (% of total)  558 (62.5%)  395 (61.7%)  163 (64.4%)  38 (58.5%)  19 (73.1%)  4 (66.7%) # in human T‐ALL, gain, loss, or LOH (% of total)  597 (66.9%)  414 (64.7%)  183 (72.3%)  45 (69.2%)  20 (76.9%)  5 (83.3%)              
Occurrence in CNAs of 75 human T­ALLs:             shared genes in >1 human T‐ALL  558  395  163  38  19  4 shared genes in >2 human T‐ALLs  347  253  94  26  11  3 shared genes in >5 human T‐ALLs  126  86  40  15  7  2 shared genes in >6 human T‐ALLs  77  50  27  9  7  2                           
Shared CNA Genes in 14 D. rerio and 61 Human Primary T­ALLs           











T­ALLs   # of genes with human homologues  768  528  240  63  25   # in human T‐ALL, gain or loss only (% of total)  472 (61.5%)  326 (61.7%)  146 (60.8%)  35 (55.6%)  18 (72.0%)   # in human T‐ALL, gain, loss, or LOH (% of total)  505 (65.8%)  344 (65.2%)  161 (67.1%)  42 (66.7%)  19 (76.0%)                
Occurrence in CNAs of 61 human primary T­ALLs:             shared genes in >1 human T‐ALL  472  326  146  35  18   shared genes in >2 human T‐ALLs  218  150  68  24  11   shared genes in >4 human T‐ALLs  93  72  21  10  7 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Supplemental material  
 
Leukemic cell isolation and FACS. GFP+ leukemic tissues were dissected under 
fluorescent microscopy into Zebrafish Kidney Stromal media. Single cell suspensions were made 
by pipetting, filtering through SmallParts 35 m filters (Miramar, FL, USA), and final passing 
through 70m Filcon filters (Becton Dickinson, San Jose, CA, USA) before analysis. Flow 
cytometry and fluorescence-activated cell sorting (FACS) were as described (Frazer, Meeker 
Rudner et al. 2009) using a BD FACSVantage instrument (Becton Dickinson). GFP intensity, 
forward- and side-scatter were used for gating. Cells were collected into Zebrafish Kidney 
Stromal media.  
Serial transplantation. Tumors were dissected and cells prepared as above. GFP+ cells 
were FACS-purified, diluted in Zebrafish Kidney Stromal media and concentrations confirmed by 
hemocytometer counts. Using a 137Cesium source, hosts were irradiated with 25 Gy, and intra-
peritoneally injected 2 days later with 1x 105 of FAC-sorted GFP+ cells in injection volumes of 
10 ul. Recipients were monitored by serial fluorescence microscopy to follow engraftment and 
disease progression. 
Array comparative genome hybridization and imaging. After FACS collection, total 
genomic DNA was extracted from collected cells as well as individual matched tail clips using 
the DNeasy Blood & Tissue Kit (Qiagen Inc., Valencia, CA). DNA collected from the tail clips 
was used as a reference (i.e. cancerous test vs. non-cancerous control) to determine CNVs using a 
self-self hybridization to reduce potential inter-individual effects. After heat denaturation, 
genomic DNA (500 ng) from the test and reference sample was labeled with Cy5-dCTP or Cy3-
dCTP by random priming using the BioPrime Labeling Kit (Invitrogen, Carlsbad, CA), in which 
fluorescently labeled nucleotides are incorporated during genomic DNA replication. 
Unincorporated nucleotides were removed using Amicon Ultra 0.5 mL 30K filters (Millipore) 
prior to the determination of DNA concentration and dye incorporation. For array hybridization, 
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3.5 µg of labeled tumor DNA was co-precipitated with 3.5 µg of reference DNA at a total volume 
of 79 µl, 25 µl of herring sperm DNA, 26 µl of blocking agent and 130 µl of hybridization 
solution were combined and denatured at 95°C for 3 minutes. Samples were then pre-hybridized 
at 37°C for 30 minutes before being placed on custom Agilent zebrafish arrays. Arrays were 
placed in individual hybridization chambers and hybridized for 40 hours at 65°C. 
After hybridization, the cover slips were removed by placing the slide into Oligo aCGH wash 
buffer I. Slides were then transferred into a second container of Oligo aCGH wash buffer I at 
room temperature containing a stir bar at 120 RPMs and washed for 3 minutes. Following the 
first wash slides were transferred to a preheated container of Oligo aCGH wash buffer II at 37°C 
circulating as above for 1 minute. Slides were then slowly removed from the solution to prevent 
streaking and placed directly into the scanner for processing. A two-color scan of the arrays was 
conducted using the Agilent G2565CA Microarray Scanner System with SureScan High 
Resolution Technology (Agilent Technologies, Inc., Santa Clara, CA) at a 3 µm resolution. 
Images were then analyzed using Agilent Feature Extraction software which normailizes the Cy3 
and Cy5 fluorescence intensities across the array and quantifies each DNA probe for color 
intensities and background intensity to produce Cy3/Cy5 log2 ratios. 
Array analysis. Copy-number analysis using the Rank Segmentation algorithm and group 
comparisons were performed employing the BioDiscovery Nexus Copy Number 5.0 software 
(BioDiscovery, El Segundo CA, USA). Copy-number analysis was performed using a 
significance threshold (p- value) of 1x10-6 and a minimal grouping of 3 affected adjacent probes.  
Thresholds for gains and losses were set such that aneuploidies were recordable, and deletions in 
the T cell receptor regions were visible in at least 90% of samples.  
For zebrafish analysis, Nexus-produced CNA calls were refined by removal of regions of 
“self-self” hybridization, when > 3Mb were amplified or deleted, or where CNAs were also 




Sample Event Boundaries 
hlk 1 trisomy chr 6 
srk 3 trisomy chr 8 
srk 3 amplification chr23:0-4,075,864 
otg 1 trisomy chr 23 
hlk 4 trisomy chr 6 
hlk 4 trisomy chr 21 
hlk 4 trisomy chr 23 
hlk 4 amplification chr1:19,044,570-24,073,766 
mMyc trisomy chr 19 
 
A gene list was created first by identifying genes altered in these CNAs on both the NimbleGen 
and Agilent platforms, and then cross referencing them to Zv6 and Zv8, respectively, to 
determine the most current official zebrafish gene names. Each zebrafish gene was then cross 
referenced to the NCBI human genome database 36.1 or sequence-searched by BLAST to 
determine a homologous human gene. Zebrafish genes who share homology with a single human 
gene were only counted once. The human gene list was then used to analyze human T-ALL 
datasets by using the “Query” function of Nexus 5. 
Human Datasets: Two human T-ALL datasets were used. The first dataset includes 47 
patients treated on Children’s Oncology Group study P9404 or Dana-Farber Cancer Institute 
study 00-01 clinical trials. Among these 25 experienced event free survival, 9 showed induction 
failure, and 13 eventually relapsed (Gutierrez et al. 2010a). The second was paired primary and 
relapse samples from 14 T-ALL treated at St Jude Children’s Research Hospital between 1993 
and 2005 (Mullighan et al. 2007). Eight of these 14 patients also contributed a germline sample 
for aCGH, and genes found to be altered in these germline samples were not included in the 









       
17 Zebrafish T­ALLs  Total CNAs  Amplifications  Deletions 
       
Nimblgen (n=8)  176  117  59 average (range)  22.0 (4‐68)  14.6 (1‐54)  7.4 (2‐14) average size (bp)    210,165  72,810 
       
Agilent (n=9)  664  218  446 average (range)  73.8 (28‐143)  24.2 (7‐81)  49.6 (22‐105) average size (bp)    189,639  143,276        
Summary (n=17)  840  335  505 average  49.4  19.7  29.7 average size (bp)    196,808  135,044               
75 Human T­ALLs  Total CNAs  Amplifications  Deletions 
       
Agilent 244K (n=47)  509  130  379 average (range)  17.8 (9‐35)  3.4 (0‐11)  14.4 (9‐25) average size (bp)    2,661,949  4,108,918        
Affymetrix 500K (n=8) or snp6 (n=20)  1069  380  689 average (range)  35.3 (3‐90)  11.6 (0‐37)  25.1 (3‐72) average size (bp)    1,759,019  1,914,300 
       












Algorithm Processing Step  D. rerio T­ALL CNA Genes    NimbleGen platform (8 samples)  311   (+) Agilent platform (9 samples)  759   (=) # of Genes in >1 CNA on either platform  1070   (‐) # of Genes present in CNAs on both platforms  127   (=) Total # of unique CNA genes  943   (‐) Genes lacking human homolgues  15 Genes not found on human genome build 36.1  2   (=) 











           















col15a1  5 (35.7%)  COL15A1  5 (6)  4 (4)  1 (2) 
tgfbr1b  5  TGFBR1  5 (6)  4 (4)  1 (2) 
lrp6  4 (28.6%)  LRP6  6 (7)  3 (3)  3 (4) 
zgc:158374  4  MANSC1  6 (7)  3 (3)  3 (4) 
osr2  4  OSR2  6 (6)  2 (2)  4 (4) 
zgc:66488  4  FBXO43  6 (6)  2 (2)  4 (4) 
pus7  4  PUS7  4 (4)  2 (2)  2 (2) 
matn4  3 (21.4%)  MATN2  4 (4)  2 (2)  2 (2) 
zgc:65779  3  RNF170  4 (6)  2 (2)  2 (4) 
zgc:77727  3  TOR1A  4 (4)  3 (3)  1 (1) 
           















zgc:153606  2 (66.7%)  C7orf60  7 (7)  1 (1)  6 (6) 
zgc:158222  2  AHCYL2  6 (7)  1 (1)  5 (6) 
zgc:114085  2  ERGIC1  6 (7)  1 (1)  5 (6) 
flt4  2  FLT4  6 (7)  1 (1)  5 (6) 
ckmt1  2  CKMT1A  0 (5)  0 (0)  0 (5) 
ckmt1  2  CKMT1B  0 (5)  0 (0)  0 (5) 
zgc:112384  2  WBP4  2 (2)  0 (0)  2 (2) 
katnb1  2  KATNB1  3 (3)  1 (1)  2 (2) 











 Treatment for acute lymphoblastic leukemia (ALL) overall has improved dramatically 
over the past 50 years. With the advent of current multi-agent chemotherapy, survival of pediatric 
patients with many forms of ALL has improved from single digits to over 80% (Silverman and 
Sallan 2003), but T-ALL lags behind with pediatric cure rates of only 70% (Pui 1998) and adult 
survival <40% (Larson et al 1998, Takeuchi et al 2002).  
The underlying etiology of T-cell malignancies is driven by a complex combination of 
genetic changes (Ferrando et al 2002.) Specific molecular alterations that are responsible for 
lymphocyte oncogenesis has come from the discovery of aberrant chromosomal translocations 
and activation of particular pathways in blast cells of ALL patients (Armstrong and Look 2005, 
Pui and Evans 1998). While a number of contributing translocations have been described 
(Ferrando and Look 2000) most cases still are not explained by these cytogenetic aberrations 
(Graux et al 2006, Harrison and Foroni 2002). Transcription factor mis-expression has also been 
implicated in T-ALL (Ferrando et al 2002) but the genetic lesions underlying this dysregulation 
are still unidentified.  
Considerable evidence suggests that genetic modifiers can act as risk factors for 
leukemia, but few heritable mutations conferring this risk are actually known (Goldgar et al 
1994). Identification of the loci responsible for these familial cases could help explain the 
mechanisms underlying malignancies of the same type. This has been a challenge to do in human 
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pedigrees, with their small sample sizes. Therefore, animal models of heritable leukemic 
predisposition were needed. 
Zebrafish are becoming a well-accepted model in which to study cancer, particularly 
hematological neoplasias, since the immune systems of humans and zebrafish are strikingly 
similar (Amatruda and Zon 1999, Trede et al 2004). Prior to studies done in our lab, two 
transgenic models have used cell-specific over-expression of mammalian proto-oncogenes 
(NOTCH and MYC) to induce zebrafish T-ALL (Chen et al 2007, Langenau et al 2003). These 
cancers faithfully recapitulate human disease that originate in the thymus and possibly kidney 
marrow and spread to peripheral blood. Although these models are innovative, they are restricted 
in scope to the known cancer pathways used to create them. 
My thesis project has continued to prove the suitability of zebrafish in the study of 
immunologic cancers. It consists of work that identifies and characterizes three new hereditary 
models of T-ALL in the zebrafish (Frazer et al 2009). In addition, it delineates the pathway 
dysregulated in one of these heritable models. Finally, my work has shown that genomic studies 
done in our models can to cross boundaries between model-organisms and humans in order to 
identify potentially important, but as yet unstudied, factors that may underlie oncogenesis and 
relapse in T-ALL. 
Our approach to unravel unknown genetic lesions underlying T-cell malignancy through 
a mutagenesis screen in the zebrafish is novel. To facilitate detection of T cell over-proliferation, 
we used a D. rerio line that fluorescently reports T cells due to the p56lck::EGFP transgene 
(Frazer et al 2009). In this work, we reported identification of three different zebrafish mutants 
that all develop heritable T-cell malignancy. We showed that each faithfully recapitulates human 
T cell disease in onset, invasion pattern, and morphology, and that their neoplastic cells are clonal 
and transplantable. Moreover, cells from each malignancy can also be transplanted serially 
(Frazer et al 2009, Rudner et al 2010), suggesting the presence of leukemia-initiating cells (LICs).  
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Once identified and characterized, these zebrafish models of T cell malignancy have 
proved useful in understanding the pathways involved in oncogenesis of T-ALL. My thesis work 
has focused on determining the factors that contribute to disease progression in otg fish. Due to 
the similarities we observed between otg and human T-ALL, we were able to test therapies that 
are used in humans to better understand whether the same pathways are altered in this disease, 
and to open the doors for testing preclinical compounds in the future. By testing the efficacy of 
DXM and single dose irradiation treatment (XRT), both of which induce apoptosis in T-ALL, I 
determined that some zebrafish T-ALL lines are susceptible to these human therapies, while the 
T-ALL of otg fish is more resistant and relapses sooner. Next, I determined that otg embryos are 
also resistant to whole-body radiation, suggesting that the mutation underlying otg creates a 
global block in apoptosis. By examining the intrinsic apoptosis pathway carefully, my thesis work 
has narrowed the possible candidates underlying this mutation to a block in post-mitochondrial 
caspase 3-mediated apoptosis.  
A mutation in any of a number of factors might result in the phenotype exhibited by otg 
embryos, as well as correlate with a predisposition to leukemia. Resistance to glucocorticoid 
treatment has been observed in ALL in humans, and studies have linked the upregulation of 
glycolysis in these leukemic cells to prednisolone resistance (Hulleman et al 2009). An alteration 
in this pathway may underlie otg. Additionally, in T-ALL particularly, expression levels of the 
GLUT1 glucose transporter, ATP citrate lyase, a critical enzyme in tumors that links glucose 
metabolism to lipid synthesis and hexokinase II, responsible for coordinating metabolic and 
apoptotic pathways at the mitochondrial membrane have also been observed to be significantly 
correlated with steroid resistance (Beesley et al 2009). 
Other pro-apoptotic factors may also be responsible. Bad, a pro-apoptotic member of the 
Bcl-2 family of proteins, has been shown previously to enhance sensitivity to radiation-induced 
apoptosis in zebrafish embryos (Jette et al 2008). A loss of function of this factor might occur by 
a direct mutation, or by a loss of function of the phosphatase required for its activation.  Once 
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activated, Bad allows for activation of post-mitochondrial apoptosis to occur. This cascade, 
beginning with the activation of cytochrome C, and culminating with the effector caspases 9 and 
3 is very well studied in both mammals (Eimon and Ashkenazi 2010), however assays to 
investigate mitochondrial activation and cytochrome c mobilization in zebrafish are just 
beginning to be developed (Kim et al 2008). While we have determined that the sequence of a 
number of post-mitochondrial apoptosis factors are normal in otg embryos (including apaf-1, 
xiap, casp9, casp3) the possibility exists that correct message may not be translated into a 
functional protein. An investigation of the localization and accumulation of these proteins by 
immunohistochemistry or western blotting may shed light on whether this transition is occurring 
productively in otg embryos after radiation treatment.  
While identifying an aberrant pathway that disrupts signaling and results in a particular 
phenotype is a useful first step toward understanding the underlying mechanism caused by a 
mutation, it is rare that this type of investigation leads to the discovery of the underlying mutation 
present in a mutant. During my thesis work, I have made a number of attempts to map the gene 
responsible for the two otg phenotypes: leukemia and resistance to irradiation-induced apoptosis. 
My first strategy utilized restriction-site associated DNA (RAD) mapping techniques followed by 
parallel and multiplexed sample sequencing of the RAD tag libraries of 16 adult leukemic fish.  
Two subsequent attempts relied on classical PCR-based microsatellite mapping techniques in 
radiation resistant embryos. Neither approach has so far yielded a map position, but we have 
recently begun to use one of the few zebrafish isogenic lines, CG-1 (Mizgireuv and Revskoy 
2006) in an attempt to decrease intra-strain polymorphisms and increase the number of 
informative microsatellite markers. An approach that has been used recently to map zebrafish 
mutants sensitive to radiation-induced apoptosis is RNA-based deep sequencing (Cicely Jette, 
unpublished). Once performed it is possible to narrow down possible candidates by assuming that 
single base-pair mutations (the type prevalent in ENU mutagenesis) will result in the formation of 
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a STOP codon. This is another technique we could use in an attempt to identify the mutation 
responsible for the phenotypes we observe in otg.  
Although the gene responsible for otg has not yet been identified, the fact that the T-ALL 
in these animals faithfully recapitulates the human disease suggests that the underlying genetic 
mechanisms may be shared between the two species. This would make zebrafish an optimal 
model to study human ALL. As part of my thesis, I linked a number of genomic aberrations seen 
in zebrafish T-ALL models with those human samples. To do this, we utilized the technique of 
array comparative genome hybridization (aCGH) and compared copy number aberrations (CNAs) 
in 17 zebrafish T-ALLs with those in 75 human samples.  This allowed us to compare genomic 
aberrations in both primary, and relapsed human disease with spontaneously occurring, as well as 
the more aggressive serially transplanted, zebrafish T-ALLs. In our investigation of primary T-
ALLs, we examined 14 zebrafish samples and 75 human samples. From those, we identified 10 
genes who were altered in at least 3 zebrafish samples and at least 4 human samples (Figure 6.1). 
One of these genes, TGFBR1, has been previously identified as having a potential role in T-ALL, 
but the other 9 genes: COL15A1, FBXO43, OSR2, MATN2, LRP6, MANSC1, PUS7, RNF170, and 
TOR1A have never, to our knowledge, been associated with the transformation or leukemogenesis 
in T-ALL.  
In addition to examining primary T-ALLs in humans and zebrafish, We focused on 
leukemias with particularly malignant clinical behavior. In addition to the 10 gene discussed 
above, we identified 6 genes encountered repeatedly in CNAs from aggressive disease in both 
specie (Figure 6.2). The genes amplified or deleted in aggressive disease may prognosticate 
therapeutic failure, or identify mis-regulated pathways governing poor outcome at the molecular 
level.  These 6 genes are: C7orf60, AHCYL2, ERGIC1, FLT4, CKMT1A and CKMT1B. While all 
have potential as candidates, the fact that loss of ACHYL2 function has been associated with both 
colon and lung cancer (ME et al 2006) suggests that its function mediating P53 contributes to 
cancer progression. Additionally, this enzyme has been shown to play a role in altered methionine 
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metabolism and global DNA methylation in liver cancer (Calvisi et al 2007). Overall, these cross-
species comparisons have identified a short list of genes whose potential importance for T cell 
malignancy will be explored in future studies.  
 Taken together, my PhD thesis work has contributed to a better understanding of T-ALL, 
and how zebrafish models of this disease can be used to improve our understanding of the 
molecular mechanisms underlying this disease in humans. This work started with the 
identification and characterization of three new models of heritable, spontaneously occurring, 
zebrafish T-ALL. In addition, the molecular pathway dysregulated in one of these models, otg, 
has been identified and studied, narrowing down the possible responsible candidates.  Finally, this 
work has taken a global approach using aCGH, and examined genome losses and gains in both 
zebrafish, and human, forms of the disease. This comparison has identified a number of genes 
that may potentially underlie transformation of T-ALLs, or the development of particularly 
aggressive disease. As an MD/PhD student, my motivation for bench science has always been the 
acquisition of knowledge that contributes to improvement in diagnosis, prognosis, and treatment 
when returning to the bedside of our patients. By developing zebrafish as a model to study a 
challenging clinical entity such as T-ALL, we have begun to bridge this gap.  
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Figure 6.1 Recurrent shared CNA genes in primary zebrafish and human T-ALLs. 
Ten CNA genes were altered in >3 primary zebrafish T-ALLs (orange) and >4 primary 
human T-ALLs” (green). The gene names are listed, and colored text groups the genes by 
CNAs which include them. 
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Figure 6.2. Recurrent shared CNA genes in passaged zebrafish or “bad outcome” human T-
ALLs. Six CNA genes were altered in 2 passaged zebrafish T-ALLs (orange) and >5 human T-
ALLs with “bad outcome” (green). The gene names are listed, and the number of bad outcome 
human samples vs. EFS human samples where the gene was altered is in parentheses. Colored 
text groups the genes by CNAs which include them.  
 
